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2. Summary
For most autoimmune diseases known, treatment options are very limited. In fact, there is not
a single autoimmune indication where a disease-specific treatment regimen has been
described. It was the aim of this work to investigate novel strategies for specific depletion of
autoreactive B cells as the root cause of many autoimmune diseases.
The first part of this thesis describes the generation of recombinant proteins that were
engineered to induce re-directed lysis of autoreactive target cells mediated via immune
effector cells. Two such proteins were designed, expressed and characterized. One fusion
protein, designated MOGxCD3, had the function of recruiting T cells to eliminate
autoreactive hybridoma cells. The other, named MOG-Fc, was engineered for the recruitment
of FcγR+ effector cells. The generation, purification, biochemical characterization, and in
vitro investigation of cytotoxicity is shown. Both recombinant proteins were found to be
functional and showed a specific redirected lysis of MOG-reactive B cells in vitro.
In the second part, the properties of the fusion protein MOG-Fc generated for recruitment of
FcγR positive effector cells were investigated using a transgenic mouse model possessing
high numbers of autoreactive B cells. As a model system, the MOG-Ig transgenic TH mouse
was chosen. This system permitted to examine the in vivo activity of the MOG-Fc fusion
protein on autoreactive B cells and antibody titers in a non-pathological situation. Likewise,
toxic effects of the recombinant fusion protein could be monitored in TH mice, due to the fact
that these mice possessed high numbers of autoreactive B cells, but typically do not show a
pathological phenotype11.
In a third part, the immunomodulatory properties of the generated Fc fusion protein were
examined in experimental autoimmune encephalomyelitis (EAE), a model of multiple
sclerosis thought to be mediated by inflammatory T cells, where demyelinating MOG-specific
autoantibodies are suggested to play an exacerbating role. It was discovered that treatment
delayed the onset of disease in the M36-induced EAE model, but was followed by a rapidly
progressive disease course, which was clinically more severe than in the untreated control
groups. Modifications of the immunodominant epitope contained within the fusion protein
had no influence on disease progression.
Taken together, this work shows that single-chain fusion proteins can be engineered to target
B cells specific for the autoantigen MOG for depletion via immune-effector mechanisms. This
was achieved by coupling the MOG extracellular domain to a C-terminally attached effector
domain consisting of either an Fc part of human IgG1 or a single-chain variable domain
(scFv) directed against CD3ε. These proteins induced the efficient depletion of MOG-specific
B cells in vitro, ex vivo and in vivo, and thus represent a novel approach for recombinant
proteins targeting autoreactive B cells in antibody-mediated autoimmunity. Due to the
exacerbating potential of the autoantigen fragment, their use as a therapeutic option in
autoimmune conditions requires further development.
3. Introduction
3.1. Autoimmune diseases
The immune system has evolved as a highly effective defensive shield against invading
pathogens, such as viruses, bacteria, fungi, protozoa and tumor cells. To combat infection,
innate immunity as well as acquired humoral and cellular immune responses act in concert to
protect the host organism. It is the recognition of non-self that lies at the heart of
immunology. However, the protection afforded by the detection of harmful pathogens comes
at a price. All lymphocytes have the intrinsic capability to recognize any given antigen, and
mechanisms are in place that ensure the deletion, silencing or inactivation of cell clones
against self antigens. Since this is not a perfect process, some of these autoreactive clones
eventually escape deletion, but they are usually rendered anergic when they encounter their
antigen in the periphery, or remain in a state of immunological ignorance. Autoimmune
responses are a natural consequence of the open repertoire of both T-cell and B-cell receptors,
which allows them to recognize any antigen, irrespective of its self- or non-self origin. In rare
instances, such autoreactive clones are reactivated from their "indifferent", or ignorant state,
and mount an adaptive immune response against self tissues. When these responses are
sustained and cause lasting tissue damage, they become medically significant and are
classified as autoimmune diseases.
3.2. Humoral autoimmunity
In most instances studied, the aetiology of human autoimmune disease has remained elusive,
even though molecular mimicry by microbial pathogens and MHC class II genotype may play
a role in predisposition to disease development1. It  is now recognized that each autoimmune
disease posesses a characteristic pathology mediated mainly by B cells (immunopathogenesis
of type II and III), T cells (type IV), or a combination thereof. In the case of type II
autoimmunity, IgM or IgG antibodies to cell surface or matrix antigens lead to tissue damage
2. Classical examples of such pathological manifestations are pemphigus vulgaris, myasthenia
gravis or Grave's disease.
Grave's disease is caused by the production of antibodies specific for the receptor for thyroid-
stimulating hormone (TSH). These autoantibodies are agonists for the TSH receptor, thereby
stimulating the production of thyroid hormones. Thus, Grave's disease manifests itself as a
disease of disrupted feedback regulation of thyroid hormone production, resulting in
hyperthyroidism3.
In myasthenia gravis, the acetylcholine receptor is the target of autoimmune attack4.
Neuromuscular transmission is blocked by antibodies predominantly against the alpha-chain
of the receptor, which is thought to result in internalization and degradation of acetylcholine
receptors found in the neuromuscular junction. Patients present with progressive weakness
and do eventually die because of their disease.
Pemphigus vulgaris (PV) is a disease of the skin, where the stratisfied epithelial cells of the
skin lose their ability to adhere to one another5. This acantholysis of keratinocytes leads to
separation of the suprabasal epidermal layer, resulting in severe and potentially fatal blister
formation in skin and oral mucosa. Loss of adhesion is thought to be mediated by antibodies
against desmosomal cadherins, such as desmoglein 3 (Dsg 3) and Dsg 1. Even though therapy
of PV with corticosteroids has proven to reduce mortality from 90 to 10%, long-term effects
are severe and can be fatal 6.
A large number of autoantigens has been identified to date, and the mode of action of many
pathogenic antibody responses directed against these target structures is known and relatively
well-understood. However, the event that may ultimately initiate an autoimmune response in
humans is still a matter of speculation. This explains why treatment options to most
autoimmune diseases are extremely dissatisfactory: they are not addressing the root cause of
the disease, but induce global suppression of the immune system as a whole. General
immunosuppression does lead to a short-term clinical improvement in the autoimmune
condition, but it also goes hand-in-hand with severe side effects, such as increased
susceptibility to infection or even the development of malignancies7.  Thus, there is an urgent
demand for more specific, non-hormonal therapeutic approaches for antibody-mediated
autoimmune diseases.
The aim of this work was to devise new ways to eradicate those cells of the immune system
that can be held accountable for the production of autoreactive antibodies, that is, the
autoreactive B cells. This goal should be accomplished by combining within a single-chain
protein a known autoantigen with a cytotoxic effector mechanism. Only those B cells
harboring a B-cell receptor reactive against the autoantigen on their cell surface would bind
this fusion protein, which should lead to a highly specific elimination of only the autoreactive
B-cell compartment, sparing B cells with other specificities. In fact, the number of
autoreactive B cells is so low that, even in individuals affected with autoimmune disease, their
presence can be monitored only indirectly via detection of secreted immunoglobulin or, in
some cases, by extremely sensitive assays, such as ELISPOT8. This poses a challenge to the
investigation of B-cell specific therapies, since the cellular compartment that needs to be
addressed cannot be readily detected in conventional experimental systems.
A core requirement for a suitable model system to investigate immunotherapeutic strategies is
the presence of large numbers of autoreactive B cells. These B lymphocytes should be easily
traceable, thereby allowing the assessment of B-cell specific interventions. While transgenic
approaches introducing immunoglobulin genes coding for anti-self B-cell receptors seem at
first glance a straightforward strategy, special consideration has to be given to the investigated
target antigen. As a matter of fact, in most of the targeted transgenic mouse models studied so
far, the regulatory potential of the immune system was able to cope even with large numbers
of transgenic autoreactive B cells, resulting in their efficient deletion or inactivation by
different means9. Thus, there are only very few cases where the transgenic expression of
autoreactive antibody results in the generation of a fully functional, autoreactive B-cell
population10. One such system is the so-called “TH mouse”11, a transgenic mouse model
system with B cells reactive against the autoantigen myelin oligodendrocyte glycoprotein
(MOG). MOG was discovered due to its pivotal role in the induction of experimental
autoimmune encephalomyelitis (EAE), a model for multiple sclerosis.
3.3. An example of a complex autoimmune disease: Multiple sclerosis
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system
(CNS). In contrast to mainly antibody-mediated afflictions, the pathology observed in MS is
thought to be centrally driven by T-helper 1 (Th1) cells. MS is the most common neurological
disease of young adults of Northern European descent, the onset of clinical symptoms usually
appearing between age 20 and 4012;13. The disease is more prevalent in women than in men,
who outnumber men with the disease at a 2:1 ratio. The cause of MS is unknown, but genetic
factors are important. The concordance rate among monozygotic twins is 30%, a 10-fold
increase over dizygotic twins or first-degree relatives14;15. An important genetic factor are
HLA class II genes, with HLA DR2 carrying a 4-fold increased risk for Northern European
caucasoids16. The clinical picture of MS typically involves an initial course, manifested by
relapse and remission for several years. In about half of the cases, the disease progresses to a
more chronic phase. Patients present with symptoms entirely attributable to pathology of the
central nervous system, which may include disturbances in visual acuity, motor disturbances
affecting walking and use of hands, incoordination, incontinence, spasticity and problems
including loss of touch, pain, and temperature. Cognitive function is not impaired in MS13.
The central nervous system shows a classic picture of inflammation extending into the myelin
sheath, as characterized by infiltration of lymphocytes, localized myelin destruction and loss
of oligodendrocytes. Intrathecal Ig synthesis, demonstrated by the presence of oligoclonal
bands in the cerebral spinal fluid of MS patients, further argues for an immune-mediated
mechanism of the disease. Due to the presence of macrophages and lymphocytes in MS
lesions, and the association of MS with MHC genotype, MS is believed to be an autoimmune
disease involving immunopathological reactions against myelin proteins. Indeed,
immunization of experimental animals with CNS antigens leads to the development of an MS-
like disease designated experimental autoimmune encephalomyelitis (EAE).
3.4. Experimental autoimmune encephalomyelitis (EAE), a model for MS
EAE shares many characteristic features with multiple sclerosis, such as histopathology,
dependence on genetic factors and clinical symptoms17. Following immunization with CNS
antigen in the periphery, an autoimmune response is initiated towards myelin antigens that
involves migration of autoreactive T lymphocytes into the CNS18, where they act in concert
with humoral autoimmunity to induce inflammation, loss of blood-brain-barrier (BBB)
integrity, migration of macrophages and, consequently, destruction of myelin leading to
neurological deficits19;20. Indeed, passive transfer of EAE by activated encephalitogenic T
cells specific for myelin basic protein (MBP) has reinforced the concept that myelin-specific
T cells may be involved in the initiation of inflammatory responses in the CNS21.
Even though the major myelin constituent MBP induces clinical disease upon immunization
in CFA, it does not induce the demyelinating plaques in primates or rats, which are so very
characteristic of MS lesions22. Besides MBP, several other CNS autoantigens were
investigated for their encephalitogenic potential, including proteolipid protein (PLP), myelin-
associated glycoprotein (MAG), myelin oligodendrocytic basic protein (MOBP) or myelin
oligodendrocyte glycoprotein (MOG). Remarkably, MOG is the only CNS antigen to elicit
both encephalitogenic T cells as well as demyelinating plaques in nonhuman primates23;24,
thus reproducing the complex pathology seen in MS. In fact, demyelination was found to be
associated with the presence of MOG-specific antibodies in CNS lesions of MOG-induced
EAE in the marmoset and also in acute multiple sclerosis lesions25. The observation that
intravenous injection of anti-MOG immunoglobulin leads to an exacerbated chronic-relapsing
disease course, after primary EAE induction via transfer of MBP-specific T cells, supports the
notion that humoral autoimmunity may play a role as an exacerbating factor in disease
progression26. However, the unusual potency of MOG as an encephalitogen, which induces
both highly pathogenic T cells as well as demyelinating autoantibodies, clearly indicate that
MOG-induced EAE is not the most suitable system to investigate therapeutic strategies aimed
at targeting solely the B-cell response in antibody-mediated autoimmunity. Therefore, the
emphasis of this work was placed on the choice of MOG as a model target auto-antigen to
investigate B-cell depletion strategies in the absence of an inflammatory context, as
encountered in EAE.
3.5. Myelin oligodendrocyte glycoprotein (MOG) as a model auto-antigen
Myelin oligodendrocyte glycoprotein (MOG) is a transmembrane protein exclusively found
on the outermost sheath of CNS myelin, making up only 0.05% of total myelin protein
content. In contrast to other proteins of the central nervous system, such as the major
constituents proteolipid protein (PLP) or myelin basic protein (MBP)27, MOG is not
expressed in the thymus. Therefore, MOG-specific T- or B-cell clones are not subject to
clonal deletion and, due to the absence of MOG in the periphery, they are not anergized or
inactivated in peripheral tissues. Thus, autoreactive B-cell clones can be maintained in the
periphery in a fully functional state, provided that the intact blood-brain-barrier (BBB)
prevents their entry into the CNS. In fact, gene targeting of a rearranged anti-MOG heavy
chain VDJ segment to replace the endogenous J region resulted in transgenic mice (TH)
almost exclusively expressing anti-MOG heavy chains in their B-cell repertoire (see Fig. 1
illustrating the gene replacement strategy)11. Here, TH stands for “transgenic heavy chain”.
Together with endogenous light chains, these transgenic Ig heavy chains assemble to form
fully functional B-cell receptors, resulting in a high proportion of MOG-reactive B cells and
also high anti-MOG autoantibody titers11. Not surprisingly, TH mice are predisposed to
develop CNS autoimmunity, like experimental autoimmune encephalomyelitis (EAE).
However, autoreactive B cells and autoantibody titers are only conditionally pathogenic upon
challenge with CNS antigen emulsified in complete Freund's adjuvant (CFA), not affecting
healthy animals. B cells develop normally in this model, since endogenous constant regions
are still present and allow for class switching, whereas endogenous light chains endow the TH
mice with the ability to respond to pathogens with an effective humoral immune response.
Taken together, the features of i) high numbers of autoreactive B cells in the periphery, ii)
high autoantibody titers and iii) normal B-cell development, make the TH mouse an ideal
model system to study strategies aimed at specifically targeting autoreactive B cells. This
work was aimed at devising such a strategy through recombinant fusion proteins
encompassing an antibody-based effector domain. The rationale is grounded in the experience
gained by using antibodies as immunotherapeutic modalities.
Fig. 1. Site-directed replacement of the JH locus with the TH MOG gene. Structure of the wild-type IgH
locus and the targeted insertion. Illustration kindly provided by Antonio Iglesias (after Litzenburger 1998).
3.6. Antibody-based therapeutic approaches
Antibodies are prototypic adaptor molecules. The intact humoral immune system has the
capacity to generate antibodies that can bind just about any molecular target structure. In its
role in defense against pathogens, an antibody has the function to mediate contact between a
pathogen’s target surface and an effector mechanism. This effector mechanism may consist of
cellular components of the immune system, such as natural killer cells (NK) or macrophages
(MO), or a cascade of enzymes like the complement system. In doing so, humoral immunity
constitutes an essential part of the immune system, and antibodies cooperate with cellular
immunity to fight off invading viruses or bacteria very effectively.
Naturally, the situation is quite different when the pathogenic moiety is not a microbe, but a
cellular component of the host. One such example is found in the grave consequences caused
by cancer cells. Once a malignant clone is growing to a tumor, it has undergone multiple
rounds of selection and found a way to escape those immunological checkpoints that usually
prevent uncontrolled proliferation of transformed cells. The immune system has devised an
intricate recognition network to eliminate diseased cells. Major anti-tumor effector
mechanisms are provided by natural killer cells (NK) and CD8+ cytotoxic T cells (CTLs).
Both effector cell populations are controlled by MHC class I. NK cells lyse only those targets
with low or absent levels of cell-surface MHC class I, while CTLs recognize tumor-associated
antigens (TAA) presented in the context of surface MHC class I and destroy the tumor cell.  A
variety of mechanisms have been described by which tumors may escape immune
recognition, including down-regulation of MHC class I molecules on the cells' surface,
alteration of the cytokine milieu within the tumor to render TAA-specific T cells anergic,
expression of molecules such as CD95L that may induce premature lymphocyte cell death28-
30, or establishment of a tissue architecture that limits the penetration of lymphocytes31;32. In
these situations, the immune system is at a loss and will not be able to cope on its own with
the danger posed from transformed self cells. It is the desire of tumor immunotherapy to make
tumor cells again visible to the immune system, thereby inducing their ultimate destruction.
The approaches are numerous and include vaccination with tumor antigens in adjuvant33;34,
DC vaccines35, completely synthetic vaccines based on tumor-specific T-cell epitopes36, ex
vivo transduction of irradiated tumor cells with recombinant adeno-associated viruses carrying
genes coding for co-stimulatory molecules37 and also vaccination approaches with a variety of
bacteria engineered to express tumor antigens when they are taken up by phagocytic cells38.
Despite the enormous efforts undertaken in order to break tolerance mainly on the T-cell level
by vaccination approaches, there is only one single approach that has so far proven
efficaceous in humans with a high success rate. These are recombinant antibodies. In fact,
several products are currently approved for use in patients and on the market (table 1)39. One
of these is the chimeric IgG1-antibody Rituxan, directed against the CD20 antigen on B
cells40;41. Rituxan has been approved for follicular Non-Hodgkin’s lymphoma (NHL). By a
mechanism relying to a large part on antibody-dependent cellular cytotoxicity (ADCC)42, this
molecule induces highly efficient killing of malignant cells in B-cell lymphomas. The CD20
antigen is expressed on essentially all B cells found in the periphery. Therefore, anti-CD20
treatment results in the depletion of the whole B-cell pool. While this is certainly an
acceptable situation in oncology, the requirements for an approach targeting B cells in chronic
autoimmune afflictions need to be more stringent.
3.7. Objectives
The aim of the work presented here was the establishment of a novel principle for the specific
targeting of autoreactive B cells through recombinant antibody-based fusion proteins. Using
TCR-specific F(ab')2 antibody fragments chemically coupled to TNP (2,4,6-trinitrophenyl),
the bridging of T-cell and B-cell receptors was demonstrated previously43, thus forcing
interactions between CTLs and TNP-specific B cells. Building upon this concept, novel
proteins can be envisioned to combine a B-cell targeting domain with an antibody effector
mechanism within a single protein chain. The choice of this effector mechanism was an
important consideration.
A number of mechanisms exist that may lead to target cell destruction through exogenously
supplied antibodies. These consist of i) antibody-dependent cellular cytotoxicity (ADCC), ii)
specific signal-inducing properties, iii) complement-dependent cytotoxicity (CDC) and iv)
induction of an anti-anti-idiotypic response.
ADCC is a major mechanism involved in target cell lysis for therapeutic antibodies such as
Rituxan42 and can be monitored in cell culture systems. Antibodies bound to the target cell
induce the recruitment of FcR-positive effector cells like natural killer cells (NK),
macrophages (MO), monocytes and granulocytes. Those effector cells recognize their target
cells when they are “decorated” with bound antibodies, which triggers the release of cytotoxic
granules through high-avidity binding of Fc receptors to multiple immunoglobulin constant
parts, and leads to destruction of the target cell. The cytotoxic potential of an antibody can be
quantitated by release of 51Cr from cells or a number of fluorescent dyes, e.g. propidium
iodide, that stain only those cells that have undergone various stages of apoptosic or necrotic
forms of cell death. The Fc part of human IgG1 has proven to be most suitable for the
induction of ADCC when compared to Fc parts of other IgG isotypes42.
Complement-mediated lysis is yet another mechanism that may lead to antibody-dependent
cell death. The most potent inducers of the complement cascade are IgM antibodies, based on
their pentameric structure. Whereas at least two IgG antibodies are required to initiate the
binding of C1q, the initiator of the classical pathway of complement, a single IgM molecule
can recruit C1q and set off the complement cascade. The role of complement fixation by
antibodies is a central mechanism in the host defense against pathogens. However, its role in
the destruction of tumor cells in vivo is largely unresolved, due to the expression of
complement inhibitory proteins on mammalian cells. Likewise, most common inbred mouse
strains have very low levels of complement as compared to other mammals. Complete lack of
complement activity has been reported for many mouse strains, attributed to the absence of
C5. For example, total hemolytic CH50 titers of <160 are observed for the SJL/J and
C57BL/6 mouse strains, in comparison to 6,666 for humans and 10,324 for guinea pig44. In
fact, the sera of these mice produce less than 22% maximum lysis at optimal serum
concentrations in standard sheep erythrocyte lysis assays. This limits the value of the mouse
as an experimental model to investigate the contribution of CDC to antibody-mediated cell
lysis.
Induction of the anti-idiotypic network and modulation of signal transduction through cell-
surface receptors are other mechanisms by which antibodies may initiate cell death of target
cells. After antibody treatment, patients may respond with an anti-idiotypic antibody (ab2)
and, consequently, with an anti-anti-idiotypic response (ab3). These ab3 responses may
support the action of the supplied therapeutic antibody, since they will again recognize the
primary antigen. In fact, vaccination strategies with anti-idiotypic antibodies directed against
the idiotype specific for the epithelial cell antigen EpCAM are currently in clinical trials for
adjuvant therapy of colon carcinoma45-47. However, the true effect of the anti-anti-idiotypic
response in supporting the action of an exogenously supplied primary antibody is still unclear.
Reports about rituximab indicate that binding to the CD20 differentiation antigen induces a
pro-apoptotic signal41. This signal-inducing effect of the antibody may add to its cell-
mediated cytotoxic properties. Similar properties were discovered for trastuzumab, a
monoclonal antibody directed against the HER2/neu surface protein. The HER2/neu
glycoprotein is over-expressed on 25-30% of breast carcinoma cells in women with metastatic
breast cancer. HER2/neu is a putative receptor tyrosine kinase involved in the survival and
growth of carcinoma cells, and trastuzumab is thought to interfere with signaling through this
receptor48.
Despite more than 15 years of experience in antibody therapy, the mechanisms that are truly
essential for a clinical response in patients have largely remained unidentified until recently.
A recent report has investigated the role of Fc receptor engagement in the therapeutic effect of
trastuzumab and rituxan in a mouse tumor model42. The investigators were able to show that
the anti-tumor effect of these monoclonal antibodies largely depends on immune activation
through the Fc receptor. The therapeutic effect of rituxan was essentially abolished in FcγRIII
knockout mice, while trastuzumab retained about 40% of its activity as compared to wild-type
mice. This result indicates that ADCC is the major mechanism to therapeutic antibody
efficacy in the mouse model. Equally intriguing is the finding that monoclonal antibody
therapy is more potent in mice lacking the inhibitory receptor FcγRIIB. Thus, approaches that
selectively engage activating receptors without affecting inhibitory Fc receptors could
increase the potency of an antibody-based drug.
Considering the findings outlined above, a strategy was devised for the construction of fusion
proteins harnessing the most promising cytotoxic effector functions. In a first recombinant
protein, the human IgG1 Fc region was fused in a C-terminal position to the human MOG
protein. The idea was to target autoreactive B cells through the MOG domain, while at the
same time recruiting Fc receptor positive immune effector cells through the IgG1 Fc domain.
Due to the bispecific nature of the protein, it was hoped that engagement of Fc receptors
would lead to the specific elimination of autoreactive target B cells. In a second approach, a
bispecific protein was generated that included human MOG in an N-terminal position fused to
a murine single-chain Fv antibody (scFv) directed against the epsilon chain of the human CD3
T-cell receptor complex. It was envisioned that these antibody fusion proteins would bind to
the MOG-reactive B-cell receptor (BCR) and recruit T cells to eliminate anti-MOG+
autoreactive B lymphocytes. The single-chain Fv format has an additional appeal in its ability
to potentially trigger T cells in the absence of the engagement of inhibitory receptors. The T-
cell recruiting fusion protein could only be tested in vitro, since its parental anti-CD3
monoclonal antibody recognizes only human CD3 epsilon and does not cross-react with the
TCR complex of other species with the exception of chimpanzees. This is in contrast to the
human IgG1 Fc part in the first fusion protein, which is known to cross-react with murine Fc
receptors and can be used in experimental mouse systems50. Here, two novel proteins were
generated, one with the validated IgG1-Fc constant region, the other with a scFv domain
directed against CD3 on human T cells. These novel bispecific proteins were evaluated for
their potential to specificially eliminate autoreactive, αMOG+ B cells.
α-CD3Auto-Antigen X
X
α-Target Cell α-CD3
scFv
A
B
X
NK cellB cell
CFig. 2. Working principle of bispecific antibody fusion proteins. A. Construction of a single-chain Fv (scFv)
antibody by combination of 2 antibody variable regions. Example shows scFv Ab targeting T cells via CD3.
B. Targeting autoreactive B cells. ScFv antibody fusion protein for recruitment of T cells to B cells reactive
against a putative auto-antigen X. Adapted from Micromet AG, 2002. C. Illustration of concept for induction
of re-directed lysis through a bispecific Fc fusion protein. B cells are targeted via autoantigen domain of
fusion protein (black) for depletion through FcγR+ effector cells, such as NK cells.
4. Material and Methods
4.1. Molecular biology
For expression of auto-antigen effector domain constructs, pEF-dhfr α(CD19xCD3)49 was
modified by removing the region coding for the single-chain αCD19 antibody. As described
below, the remaining αCD3 expression cassette was used for insertion of cDNA coding for
the auto-antigenic domain of the human MOG protein and provides an ideal system for
further cloning of auto-antigen x αCD3 fusion proteins.
4.1.1. Isolation of RNA from MOG-transfected fibroblasts
Total RNA was isolated from MOG-transfected fibroblasts (kindly provided by Chris Lining-
ton, MPI Neurobiology Martinsried) using the Qiagen RNEasy RNA Extraction Kit according
to the manufacturer’s suggestions. RNA was dissolved in H2O and stored at –80°C.
4.1.2. Reverse transcription
Using isolated RNA from 4.2.1. as a template, cDNA was synthesized as follows:
2 µg total RNA were added to 0.5 µg Oligo-dT primer in a total reaction volume of 12 µl. The
reaction mixture was incubated at 70°C for 10 min. Then, 4 µl 5x First Strand Buffer (Gibco
BRL), 2 µl 0.1 M DTT and 1 µl 10 mM dNTPs were added. Incubation was performed at
42°C for 2 min, after which 200 U of Superscript II Reverse Transcriptase (RT) (Gibco BRL)
were added. The reaction mixture was incubated for 50 min. at 42°C. Then, RT was
inactivated due to a 15 min incubation step at 70°C. Isolated cDNA was stored at –20°C.
4.1.3. Amplification of MOG-coding cDNA fragments
In order to obtain cDNA coding for the extracellular domain of the human MOG protein
(MOG-ex), the following primers were chosen:
Primer 1 (MOG-Ex 5‘): 5‘-TAGAATTCATGGCAAGCTTATCGAGACCC-3‘
Primer 2 (MOG-Ex 3‘): 5‘-CATCCGGATCCAGGGCTCACCCAGTAGA-3‘
Primers were designed as to allow amplification of the first 462 bases of the region coding for
both leader sequence and extracellular domain of the human MOG protein, while introducing
EcoRI and BspEI restriction sites at 5‘ and 3‘ ends of the amplified fragment, respectively.
This leads to a final product of 474bp of length.
4.1.4. Polymerase chain reaction (PCR)
For PCR, 50 pmol/ each of appropriate primer, 1 µl dNTPs 10 mM, 4 µl cDNA, 5 µl Pfu-
buffer 5x (Stratagene) and 5 U Pfu-Polymerase (Stratagene) were added to a final volume of
50 µl in H2O, and specific cDNA was amplified by PCR.
4.1.5. Construction of MOGxCD3 encoding expression vector
In order to obtain the desired construct, expression vector α(CD19xCD3) pEF-dhfr was sub-
jected to restriction with EcoRI and BspEI, leading to removal of the fragment coding for
anti-CD19. The remaining vector-anti CD3 portion was gel-extracted (gel extraction kit,
Qiagen). Equally, MOG-ex was partially digested with BsaWI and EcoRI, and the
corresponding fragment of 474bp of length was isolated via gel-extraction as described above.
BsaWI restriction was chosen due to this enzyme’s insensitivity to dam-methylation at the
original BspEI restriction site. DNA was eluted in 30 µl Tris pH 8.5 and stored at –20°C.
Ligation of isolated DNA fragments was performed with equal volumes of extracted DNA
and 5 U of T4 DNA Ligase in a total volume of 20 µl in 1x T4 buffer (Roche Biochemicals).
Ligation was allowed to proceed for 30 min. at room temperature (RT). Of each ligation
reaction, 3 µl were used to transform E. coli XL-1 Blue as described above. Colonies were
picked and subjected to MiniPrep analysis. Following analytical restriction enzyme digestion,
appropriate clones were sequenced (Sequiserve, Vaterstetten). Correct clones were grown in
300 ml LB-Amp medium, and plasmid DNA was isolated using the Qiagen plasmid prep kit
as described above. Again, integrity of isolated DNA was verified via restriction enzyme
analysis.
4.1.6. Construction of MOG-Fc encoding expression vector
4.1.7. Isolation of RNA from HD69-transfected CHO cells
Total RNA was isolated from HD69-transfected CHO cells51 using the Qiagen RNEasy RNA
Extraction Kit according to the manufacturer’s suggestions. RNA was dissolved in H2O and
stored at –80°C.
4.1.8. Reverse transcription
Using isolated RNA from 2.1. as a template, cDNA was synthesized as follows:
2 µg total RNA were added to 0.5 µg Oligo-dT primer in a total reaction volume of 12 µl. The
reaction mixture was incubated at 70°C for 10 min. Then, 4 µl 5x First Strand Buffer (Gibco
BRL), 2 µl 0.1 M DTT and 1 µl 10 mM dNTPs were added. Incubation was performed at
42°C for 2 min, after which 200 U of Superscript II Reverse Transcriptase (RT) (Gibco BRL)
were added. The reaction mixture was incubated for 50 min. at 42°C. Then, RT was
inactivated due to a 15 min incubation step at 70°C. Isolated cDNA was stored at –20°C.
4.1.9. Amplification of IgG1-coding cDNA fragments
In order to obtain cDNA coding for the Fc-domain of the human IgG1 antibody backbone, the
following primers were chosen:
Primer 3 (IgG1-Fc 5‘): 5‘-TATCCGGAGAGCCCACCTCTTGTGACAAAAC-3‘
Primer 4 (IgG1-Fc 3‘): 5‘-GTGTCGACTCATTTACCCGGAGACAGGG-3‘
Primers were designed as to allow amplification of the 699 bases coding for the Fc part of the
human IgG1 backbone, while introducing BspEI and SalI restriction sites at 5‘ and 3‘ ends of
the amplified fragment, respectively. This leads to a final product of 711bp in length.
4.1.10. Polymerase chain reaction (PCR)
For PCR, 50 pmol each of appropriate primer, 1 µl dNTPs 10 mM, 4 µl cDNA, 5 µl Pfu-
buffer 5x (Stratagene) and 5 U Pfu-Polymerase (Stratagene) were added to a final volume of
50 µl in H2O, and specific cDNA was amplified by PCR.
4.1.11. PCR product purification
DNA was recovered from PCR reaction mixture according to the manufacturer’s suggestions
(Roche Applied Biosciences).
4.1.12. Ligation of PCR products into pCR-Script Amp vector
Blunt-ended PCR products generated by Pfu DNA polymerase were ligated into pPCR-Script
Amp vector (Stratagene #211188).
4.1.13. Transformation
Plasmids were transformed into competent E. coli strain XL-1 Blue using 4 µl of ligation
product added to 50 µl of E. coli. The mixture was incubated on ice for 10 min., 1 min. at
42°C, and then again on ice for 2 min. Thereafter, 150 µl LB-medium were added and ex-
pression of ampicillin resistance genes was induced due to 45 min at 37°C while shaking.
Reaction mixtures were plated on LB-Amp Agarose plates (50 µg ampicillin/ml) and incu-
bated at 37°C for 16 h.
4.1.14. Preparation of plasmid DNA/ MiniPreps
Colonies were picked and grown in LB-Amp medium (100 µg/ ml) for 8-12h. Bacteria were
spun down, and plasmid DNA was isolated according to manufacturer’s suggestions (Plas-
mid Mini-Kit, Qiagen). DNA was subjected to restriction enzyme analysis, and suitable
clones were sequenced (SequiServe, Vaterstetten).
4.1.15. Preparation of plasmid DNA/ MaxiPreps
Correct clones were grown in 300 ml LB-Amp medium, and plasmid DNA was isolated using
plasmid maxi kit (Qiagen).
4.1.16. Construction of expression vector coding for MOG-Fc fusion protein
In order to obtain the desired construct, expression vector α(CD19xCD3) pEF-dhfr was sub-
jected to restriction with EcoRI and SalI, leading to removal of the fragment coding for
α(CD19xCD3). The remaining linearized vector was gel-extracted (gel extraction kit,
Qiagen). Equally, MOG-ex was partially digested with BsaWI and EcoRI, and the
corresponding frag-ment of 474bp of length was isolated via gel-extraction as described
above. BsaWI restriction was chosen due to this enzyme’s insensitivity to dam-methylation at
the original BspEI re-striction site. DNA was eluted in 30 µl Tris pH 8.5 and stored at –20°C.
Ligation of isolated DNA fragments was performed with equal volumes of extracted DNA
and 5 U of T4 DNA Ligase in a total volume of 20 µl in 1x T4 buffer (Roche Biochemicals).
Ligation was allowed to proceed for 30 min. at room temperature (RT). Of each ligation
reaction, 3 µl were used to transform E. coli XL-1 Blue as described above. Colonies were
picked and subjected to MiniPrep analysis. Following analytical restriction enzyme digestion,
appropriate clones were sequenced (Sequiserve, Vaterstetten). Correct clones were grown in
300 µl LB-Amp medium, and plasmid DNA was isolated using the Qiagen plasmid prep kit as
described above. Again, integrity of isolated DNA was verified via restriction enzyme
analysis.
4.2. Cell culture and biochemical analysis
4.2.1. Expression and purification of MOGxCD3 fusion protein
4.2.1.1. Stable transfection of CHO cells
CHO cells were plated at 3x105/well in tissue culture 6-well plates and incubated at 37°C
overnight. 3 µg of DNA were pipetted in sterile Eppendorf tubes, supplemented with 100 µl
MEM-α medium (Gibco BRL) and 10 µl SuperFect transfection reagent (Qiagen) and incu-
bated for 10 min. at RT. 600 µl of MEM-α medium were added, and the reaction mixture was
transferred to CHO cells. Following a 2 h-incubation at 37°C, the supernatant was aspirated,
cells were washed once with PBS, and 2 ml MEM-α medium (10% FCS, HT-supplement
1:100) were added to each well. Transfection efficiency was determined to be 10% via stan-
dard β-galactosidase control transfection. After 24h at 37°C, transfected cells were trans-
ferred to 10 ml cell culture bottles (Nunclone ∆, Nalge Nunc International) and selected for
expression of the dhfr marker via growth in non-supplemented MEM-α medium plus 10% di-
alysed FCS. Following two passages of confluent cells at 1:5 splitting ratios, transfectants
were further selected by addition of 20 nM MTX to the selection medium. Cells were
passaged 3 times, whereafter MTX concentration was increased to 100 nM. Following a
further 3 passages, MTX was added to a final concentration of 500 nM.
4.2.1.2. Purification of expressed MOGxCD3 fusion protein
Stably transfected CHO-cells were transferred to 500 ml roller-bottles (Nalge Nunc Interna-
tional) in 250 ml MEM-α, 500 nM methotrexate (MTX) and 5% dialysed FCS. The following
day, another volume of medium was added without FCS to obtain a final concentration of
2.5% FCS. Cells were grown for 1 day post confluency. Cells were separated from the
supernatant by centrifugation at 4500 rpm, 30 min. in a Rotanta 46 centrifuge (Hettich), and
recombinant protein was purified from cell culture supernatant as follows:
The MOGxCD3 protein was isolated in a three-step purification process including cation ex-
change chromatography, immobilized metall affinity chromatography (IMAC) and gel filtra-
tion.
The final product had a molecular weight of approximately 45 kDa under native conditions as
determined by gel filtration in PBS. This corresponds to a monomeric form of the
MOGxCD3.
The purity of the isolated protein was >95% as determined by SDS-PAGE. Under the condi-
tions applied, the molecule appeared at approximately 45 kD in its monomeric form.
The final yield of purified protein was approximately 2.4 mg / l cell culture supernatant.
The GradiFrac System (Pharmacia) was used for chromatography. All chemicals were of
research grade and purchased from Sigma (Deisenhofen) or Merck (Darmstadt).
Cation exchange was performed on a HiTrap SP Sepharose column (Pharmacia) that was
equilibrated with buffer A1 (20 mM MES, pH 5.5). Cell culture supernatant was diluted 2:1
with buffer A1 and applied to the column (10 ml) with a flow rate of 4 ml/min. Unbound
sample was washed out with buffer A1 and the bound protein was eluted with 100% buffer
B1 (20 mM MES, pH 5.5, 1 M NaCl). Eluted protein fractions were pooled for further
purification.
IMAC was performed, using a HisTrap column (Pharmacia) that was loaded with NiSO4 ac-
cording to the manufacturer‘s protocol. The column was equilibrated with buffer A2 (20 mM
NaPP, pH 7.5, 0.4 M NaCl), and the sample was diluted 2:1 with buffer A2 to obtain a pH of
7. The sample was applied to the column (2 ml) with a flow rate of 1 ml/min and the column
was washed with buffer A2 to remove unbound sample. Bound protein was eluted using a
linear gradient of buffer B2 (20 mM NaPP pH 7.5, 0.4 M NaCl, 0.5 M Imidazol) (0-100%
buffer B2 in 10 column volumes). Eluted protein fractions were pooled for further
purification.
Gel filtration chromatography was performed on a Sephadex S200 HiPrep column (Pharma-
cia) equilibrated with PBS (Gibco). Eluted protein samples (flow rate 1 ml/min) were sub-
jected to SDS-Page and Western blotting for MOGxCD3 detection. The column was previ-
ously calibrated for molecular weight determination (molecular weight marker kit, Sigma
MW GF-200).
Protein concentrations were determined using protein assay dye concentrate (BioRad) and
IgG (BioRad) as standard protein.
SDS-PAGE under non-reducing conditions was performed with precast 4-12% Bis-Tris gels
(NOVEX). Sample preparation and  application were according to the manufacturer‘s proto-
col. The molecular weight was determined with SeeBlue protein standard (NOVEX). The gel
was stained with colloidal Coomassie (NOVEX protocol).
4.2.1.3. Protein analysis MOGxCD3
4.2.1.3.1. SDS-PAGE
For each peak detected, corresponding fractions were pooled and analyzed for purity via SDS-
PAGE, followed by coomassie staining. Of each pool, 5 µl were run on a Bis-Tris Gel 4-12%
(NuPage), using MOPS/SDS as running buffer.
4.2.1.3.2. Western blotting
Fractions were subjected to SDS-PAGE as described above. Protein was blotted to reinforced
nitrocellulose membrane (Optitran BA-S 83, Schleicher & Schuell) at 200 mA for 1 h
(blotting buffer: 48 mM Tris, 39 mM Glycin, 0.01 % SDS). Recombinant fusion protein was
detected with the anti-MOG monoclonal antibody 8.18-C5 at 5 µg/ml in PBS; bound anti-
MOG ab was detected via anti-mouse IgG antibody, AP-conjugated at 1:10000 in PBS
(Sigma A-2429). The membrane was stained with BCIP/NBT (Sigma B-5655).
4.2.2. Expression and Purification of MOG-Fc fusion protein
4.2.2.1. Stable transfection of CHO cells
CHO cells were plated at 3x105/ well in tissue culture 6-well plates and incubated at 37°C
overnight. 3 µg of DNA were pipetted in sterile Eppendorf tubes, supplemented with 100 µl
MEM-α medium (Gibco BRL) and 10 µl SuperFect transfection reagent (Qiagen) and incu-
bated for 10 min. at RT. 600 µl of MEM-α medium were added, and the reaction mixture was
transferred to CHO cells. Following a 2 h-incubation at 37°C, the supernatant was aspirated,
cells were washed once with PBS, and 2 ml MEM-α medium (10% FCS, HT-supplement
1:100) were added to each well. Transfection efficiency was determined to be 10% via stan-
dard β-galactosidase control transfection. After 24 h at 37°C, transfected cells were trans-
ferred to 10 ml cell culture bottles (Nunclone ∆, Nalge Nunc International) and selected for
expression of the dhfr vector via growth in non-supplemented MEM-α medium plus 10% di-
alysed FCS. Following two passages of confluent cells at 1:5 splitting ratios, transfectants
were further selected by addition of 20 nM MTX to the selection medium. Cells were
passaged 3 times, whereafter MTX concentration was increased to 100 nM. Following a
further three passages, MTX was added to a final concentration of 500 nM.
4.2.2.2. Purification of expressed MOG-Fc fusion protein
Stably transfected CHO-cells were transferred to 500 ml roller-bottles (Nalge Nunc Interna-
tional) in 250 ml MEM-α, 500 nM MTX and 5% dialysed FCS. The following day, another
volume of medium was added without FCS to obtain a final concentration of 2.5% FCS. Cells
were grown for 1 day post confluency. Cells were separated from the supernatant by cen-
trifugation at 4500 rpm, 30 min. in a Rotanta 46 centrifuge (Hettich), and recombinant protein
was purified using a 1-step purification procedure via Protein A affinity chromatography
(HiTrap Protein A column, Pharmacia) on the GradiFrac System (Pharmacia). The column
was equilibrated with 10 ml of buffer A (20 mM Tris pH 7.2), and 500 ml of cell culture
supernatant were passed through the column. Flow rate was 2 ml/ min. Bound Protein was
eluted with 20 mM citrate, pH 3, using a linear gradient. Fusion protein yield amounted to 10
mg/l. Protein was > 95% pure as assessed by Coomassie staining.
4.2.2.3. Protein analysis MOG-Fc
4.2.2.3.1. SDS-PAGE
For each peak detected, corresponding fractions were pooled and analyzed for purity via SDS-
PAGE, followed by coomassie staining. Of each pool, 5 µl were run on a Bis-Tris Gel 4-12%
(NuPage), using MOPS/SDS as running buffer.
4.2.2.3.2. Western blotting
Fractions were subjected to SDS-PAGE as described above. Protein was blotted to reinforced
nitrocellulose membrane (Optitran BA-S 83, Schleicher & Schuell) at 200 mA for 1h (blotting
buffer: 48 mM Tris, 39 mM Glycin, 0.01 % SDS). Recombinant fusion protein was detected
with anti-MOG monoclonal antibody (8.18-C5, kindly provided by Chris Linington, MPI
Neurobiology, Martinsried) at 5 µg/ ml in PBS; bound anti-MOG ab was detected via anti-
mouse IgG antibody, AP-conjugated at 1:10000 in PBS (Sigma A-2429). For detection of the
human IgG1-Fc domain, recombinant protein was blotted as described above, and the Fc
domain was stained with α-human IgG1 ab, Fc-specific, coupled to alkaline phosphatase
(AP), at 1:10000 in PBS (Sigma A-9544). The membrane was stained with BCIP/NBT
(Sigma B-5655).
4.2.3. Binding of auto-antigen fusion protein to auto-antibody
4.2.3.1. Source of auto-antibodies
The hybridoma 8.18-C552 was cultivated in serum-free medium (Gibco). Cells were separated
from supernatant by centrifugation, and mouse anti-MOG monoclonal IgG1 antibodies were
purified using a 1-step purification procedure via Protein G affinity chromatography (HiTrap
Protein G column, Pharmacia) on the GradiFrac System (Pharmacia). Column was
equilibrated with 10 ml of buffer A (20 mM Tris-HCl, pH 7.2), and 500 ml of cell culture
supernatant were passed through the column. Flow rate was 2 ml/min. Bound protein was
eluted with 20 mM citrate, pH 3, using a linear gradient. Antibody yield amounted to 4.5
mg/l. Protein was > 95% pure as assessed by Coomassie staining
4.2.3.2. Sandwich-ELISA for detection of MOG-Fc fusion protein
Isolated αMOG ab 8.18-C5 was used to detect purified MOG-Fc fusion protein and to verify
existence of 1) functional extracellular domain of MOG protein and 2) Fc effector domain in
the recombinant protein. MaxiSorp 96-well plates (Nalge Nunc International) were coated
with α-MOG at 5 µg/ ml overnight at 4°C. Plates were blocked with 1% BSA for 1 h at RT,
washed with PBS/ 0.05% Tween 20. Plates were incubated with various dilutions of MOG-Fc
fusion protein in PBS for 1 h at RT, and bound fusion protein was detected using α-human
IgG1 ab, Fc-specific and AP-conjugated (Sigma A-9544) at 1: 10,000. Alkaline phosphatase-
conjugated antibody was stained with pNPP (Sigma N-2770) and quantitated on the Spec-
traFluor ELISA reader (Tecan).
4.2.3.3. Sandwich-ELISA for detection of MOGxCD3 fusion protein
Isolated αMOG ab 8.18-C5 was used to detect purified MOGxCD3 fusion protein and to ver-
ify existence of 1) functional extracellular domain of MOG protein and 2) anti-CD3 effector
domain in the recombinant protein. MaxiSorp 96-well plates (Nalge Nunc International) were
coated with αMOG at 5 µg/ ml overnight at 4°C. Plates were blocked with 1% BSA for 1h at
RT, washed with PBS/0.05% Tween 20. Plates were incubated with various dilutions of
MOGxCD3 fusion protein in PBS for 1 h at RT, and bound fusion protein was detected using
αMT101ab (Davids Biotechnology, DabioPrep 2 Batch 2), an antibody specifically developed
against the CD19xCD3 scFv described above. Bound chicken ab was detected using AP-
coupled donkey-α-chicken ab at 1:10000 (Dianova 703-055-155).  Alkaline phosphatase-
conjugated antibody was stained with pNPP (Sigma N-2770) and quantitated on the
SpectraFluor ELISA reader (Tecan).
4.3. Binding of auto-antigen fusion proteins to immune effector cells
4.3.1. Isolation of PBMCs
Buffy coats were diluted 1:2 in PBS and separated in Ficoll gradient of density 1.077 (Sero-
med Cat.No. L 6115). Lymphocytes were separated and washed twice with PBS. Erythrocytes
were lysed with lysis buffer (8.29 g NH4Cl cell culture tested (Sigma A-0171), 1.0 g  KHCO3
0.037 g EDTA, cell culture tested (Sigma E-6511); H2O ad. 1 l).
Thrombocytes were separated during 20 min of centrifugation at 100 x g. Remaining
Lymphocytes were transferred to cell culture bottles and stored at 37°C/ 5% CO2.
4.3.2. Isolation of CD3+ cells
Human T-cell enrichment columns (R&D Systems Cat. No. HTCC-500/525) were used for
isolation of T-cells according to manufacturer’s suggestions.
4.3.3. Binding assay of MOGxCD3 to CD3+ PBMCs
To explore the binding of the MOGxCD3 fusion protein to CD3+ cells, 200,000 CD3+ cells
were added to each well of a V-bottom microtiter plate (Greiner Labortechnik). Recombinant
MOGxCD3 protein was added to obtain final concentrations of 0.032 up to 100 µg/ ml in a
total volume of 50 µl per well. Bound fusion protein was detected via binding of 8.18-C5
diluted 1:1000 in FACS-buffer (PBS 1x, 0.05% NaN3, 1% FCS), whereafter bound mouse
monoclonal ab was stained with α-mouse IgG-FITC (Sigma F-6257) at 1:40 dilution.
4.3.4. Binding assay of MOG-Fc to FcγR+ cell line p388.D1
Binding of MOG-Fc to a murine macrophage cell line was investigated in FACS. The
monocyte/macrophage cell line p388.D153 expressing murine Fc receptors was incubated with
MOG-Fc. Bound MOG-Fc was detected via FITC-labeled anti-human Fcγ antibody by flow
cytometry. Binding was quantitated and expressed as mean fluorescence intensity (MFI).
4.4. Antibody-dependent cellular cytotoxicity
4.4.1. Establishment of cell-surface αMOG-positive hybridoma cell line
8.18-C5 hybridoma cell line52 (kindly provided by C. Linington, MPI Neurobiology,
Martinsried) was adapted to serum-free medium (Hybridoma SFM, Gibco). Cells were
passaged 1:5 every third day, and cultured in 100% SFM for a period of 4-5 months.
Thereafter, MOG-reactivity in the hybridoma pool was assessed by FACS-analysis, using
biotinylated MOG protein for staining.
4.4.2. FACS-based ADCC assay
A FACS-based assay54;55 was performed using freshly isolated human PBMCs as effector
cells (ECs) for the MOG-Fc fusion protein and isolated human T cells for the MOGxCD3
fusion protein (see above). ECs and 8.18-C5 target cells were incubated overnight at 37°C/
5% CO2 at an E:T ratio of 10:1 and serial dilutions of fusion protein added in a constant
volume of 20µl to 180µl cell suspension. Cells were stained with FITC-labeled goat-anti-
mouse IgG antibody (Pharmingen 12064D) and propidium iodide. The live target cell
population was measured as percentage of the whole cell population analyzed. Unspecific
background (bg) was measured in the absence of protein. Cytotoxicity (CT) was calculated as
CT =  100 x (1-(live target cells in sample/ live target cells in control)). Background staining
of human PBMCs incubated alone was subtracted. Values greater 100% were due to slight
proliferation of PBMCs. To verify that reduction in the number of live target cells was due to
cell lysis as opposed to a growth inhibitory effect, target and effector cells were incubated
with the optimal dose of MOG-Fc (10 µg/ml) as described above, and PI-positive dead target
cells measured in FACS and expressed as percentage of total target cells detected. Cell lysis
(CL) was calculated as CL = 100 x (dead target cells)/(total number of target cells). Error bars
represent standard deviation values (S.D.) from triplicates.
4.5. Binding analysis of MOG-Fc fusion protein to mouse splenocytes
Mice were sacrificed and the spleen was removed. Single-cell suspensions were generated by
passage through a sterilized tissue-culture sieve in DMEM medium. Erythrocytes were
removed by incubation in erythrocyte lysis buffer (8.29 g NH4Cl cell culture tested (Sigma A-
0171), 1.0 g  KHCO3 0.037 g EDTA, cell culture tested (Sigma E-6511); H2O ad. 1L) for 10
min. on ice. Cells were washed with PBS/ 1% FCS/ 0.05% NaN3 and stained with the
appropriate combination of antibodies as described. Cells were incubated with fusion protein,
and bound MOG-Fc was detected with goat anti-human IgG FITC antibody (ICN 67-217).
FACS analysis was carried out on a FACS Calibur (Becton Dickinson) using CellQuest
software.
4.6. Ex vivo elimination of B cells by MOG-Fc
Splenocytes from TH mice (SJL/J background) were prepared. Single-cell suspensions were
incubated with MOG-Fc (10 µg/ml) for 16 h at 37°C/ 5% CO2 in DMEM/10% FCS in 5 ml
cell culture polypropylene vials (Becton-Dickinson) at a density of 4x106 cells/ml.
Lymphocyte analysis was carried out by FACS using antibodies against IgMa, IgD, Thy1 and
CD19 (all BD Pharmingen). All tests were performed in triplicates.
4.7. In vivo depletion of B cells in TH mice by MOG-Fc
Female TH SJL/J-mice were treated twice with 100 µg of MOG-Fc in 500 µl PBS through i.p.
injection (n=5). Blood was collected each day after treatment, PBLs were prepared, and
lymphocytes were analyzed via FACS (FACSCalibur, Becton-Dickinson). MOG+ B cells
were quantitated and normalized as percentage of total B220+ B cells detected in the
lymphocyte gate. Biotinylated rMOG concentrations were chosen as to induce complete
competitive inhibition of MOG-Fc binding. The experiment was repeated with TH mice on
BL/6 background and yielded comparable results.
4.8. Transfer of transgenic B cells into recipient wild-type mice
Spleen cells of TH mice were stimulated with LPS (Sigma, 10 mg/ml) for 3 days. Non-B cells
were then separated through incubation with biotinylated anti-CD43 Abs followed by sorting
with Streptavidin-coupled magnetic beads (Dynabeads® M-280, Dynal, Oslo, Norway). 15
mice were injected i.v. with 1.6 x 107 purified B cells. The next 3 days each 5 mice received a
daily i.p. injection of either 100 µg recombinant MOG-Fc protein or 100 µg human IgG1 Ab,
or PBS, respectively.  Three days after the last i.p. injection, peripheral blood was taken from
each mouse and the levels of transferred B cells as well as of the anti-MOG Ab-titer was
determined in FACS and ELISA experiments, respectively.  To this time point, six days after
the B cell transfer, most LPS-stimulated TH B cells expressed low levels of MOG-binding,
surface IgG, detected by double staining with biotinylated MOG, followed by streptavidin-
phycoerythrin and with goat anti-mouse IgG (Fc-specific) (BD-Pharmingen).
4.9. Detection of αMOG-Fc immune responses in ELISA
Specific Abs were detected in ELISA assays as follows: microtiter plates coated with
recombinant MOG protein or recombinant human IgG151 at a concentration of 10 µg/ml were
incubated with individual sera at three different dilutions (1:10, 1:100 or 1:1000), and bound
Abs were detected with alkaline phosphatase-labeled goat anti-mouse IgM or goat anti-mouse
IgG Abs (BD-Pharmingen). Values for IgM correspond to the 1:100 dilution and values for
IgG correspond to the 1:1000 dilution.  The levels of serum MOG-Fc protein were determined
in ELISA by coating plates with purified anti-MOG mAb 8.18-C5 (10 µg/ml) and developing
bound protein with biotin-conjugated, monoclonal anti-human IgG (Fc-specific, clone HP-
6017, Sigma, St. Louis, USA), followed by streptavidin-alkaline phosphatase and p-
nitrophenyl phosphate (Sigma) incubation.
4.10. Immunomodulatory effects of MOG-Fc treatment in EAE
4.10.1. Induction of EAE
For conventional immunization, the antigen solution was mixed with equal volumes of
complete Freund's adjuvant (CFA). This mixture was forced through a 24G tube (Hamilton)
fixed between two syringes until a hard emulsion was obtained. After anesthesia with ether,
mice were given injections of a total of 100 µg of antigen in a volume of 200 µl of emulsion.
Female SJL/J mice (Charles River) were injected in the flanks and footpads. 300 ng of
pertussis toxin in PBS were injected intraperitoneally on the day of immunization and again
48 hours later.
4.10.2. Clinical evaluation of EAE
Weight was measured daily and clinical disease was assessed after immunization with the
encephalitogen. The animals  were scored for clinical signs of EAE according to the following
scale:
0 no signs of disease
1 loss of tail tone
2 partial paralysis of one or both hindlimbs
3 complete paralysis of one or both hindlimbs
4 complete paralysis of one or both hindlimbs, paralysis of fore limbs
5 moribund or dead
4.11. Determination of T cell fine specificity against MOG M36 epitope
4.11.1. Peptide synthesis
The M36 region contained within the MOG extracellular domain was synthesized as a 15-mer
peptide (EuroGentech). A set of singly substituted peptides was generated, each peptide
carrying a single amino acid substitution to alanine from position 1 to position 15 (alanine
scan).
4.11.2. T-cell proliferation assay
Proliferation response of M36-specific T-cell-line (kindly provided by A. Iglesias, MPI
Neurobiology Martinsried) to ala-substituted peptides was tested via standard 3H-thymidine
incorporation assay. Briefly, T-cells were cultured for a period of 14 days post re-stimulation
with wild-type peptide. For assessment of proliferation, T cells were transferred to
restimulation medium (DMEM complete, 5% FCS). Wild-type SJL/J splenocytes were
prepared by standard protocol (see 4.5.) and irradiated with 4000 rad for use as APCs. The
assay was set up in flat-bottom 96-well tissue culture plates. APCs and T cells were seeded at
10:1 (106:105 per well) and incubated with 10µg/ ml of peptide at 37°C/ 5% CO2. After 48
hours, the cells were pulsed with 3H-thymidine (1µCi/ ml). Thymidine incorporation was
investigated 16 hours later.
4.11.3. Peptide competition assay
Thymidine incorporation assay was performed to investigate the ability of the mutated
peptides to function as T-cell antagonists, thus excluding interactions solely mediated through
decreased binding to MHC II56;57. APCs were pre-pulsed with 10 µg/ ml of wt M36 peptide
for 2h at 37°C/ 5% CO2. Cells were then washed with restimulation medium and incubated
with 10µg/ ml of the substituted M36 variants. Proliferation was assessed as described in
4.11.2.
4.11.4. Cloning of mutated MOG-Fc constructs
Site-directed mutagenesis was performed by standard protocol. Briefly, primers were
synthesized covering the 5' and 3' terminal sequence (5': A, 3': D) of the region encoding the
MOG extracellular domain. For mutagenesis, primers were chosen to include the desired
nucleotide exchanges flanked by 15 to 20 bases to both the 3' and 5' end (forward primer (5'):
C, backward primer (3'): B). Primers A and B were used in PCR to generate fragment I.,
primers C and D generated fragment II, each using MOG-Fc as a template. Following gel
extraction, fragments I. and II. were used as templates to synthesize mutated MOG-Fc with
primers A and D. This resulted in mutated constructs encoding MOG-Fc carrying a single
amino acid substitution to alanine at position 10 of the M36 region (R-MOG), and another
variant carrying a single substitution to alanine at position 13 (S-MOG). Transfection of CHO
cells, selection of stable transfectants and purification of protein were carried out exactly as
described for the wild-type MOG-Fc protein.
4.11.5. Selective binding of mutated MOG-Fc to autoreactive B cells
Whole lymphocytes from transgenic knock-in mice were prepared from spleen as described
elsewhere11. Cells were incubated with fusion protein, and bound MOG-Fc was detected with
goat-anti-human IgG FITC antibody (ICN 67-217). The subsequent incubation with anti-IgM,
anti-B220, and anti-CD5 Abs was performed on ice for 20 min.
4.12. Treatment of mice
Female SJL/J mice were immunized with PLPs peptide on day 0. TH B cells were transferred
24 hours later via intravenous injection through the tail (see section 4.8.). On day 7 post-
immunization, mice were treated with 100 µg of MOG-Fc protein ("wild-type"), 100 µg R-
MOG and 100 µg S-MOG. Treatment was repeated on days 8 and 9. Mice were scored for
clinical signs of EAE throughout the experiment, and weight changes were recorded daily.
5. Results
5.1. Design, expression and biochemical characterization of fusion proteins
Bispecific fusion proteins targeting autoreactive B cells must conform to a number of
theoretical considerations. Informed choices had to be made regarding the selected expression
system and the purification protocol. The structural integrity of the recombinant proteins was
investigated by SDS-PAGE, Western blotting and ELISA analysis.
5.1.1. Choice of expression vector
The expression vector pEFdhfr was chosen in conjunction with dhfr-deficient chinese hamster
ovary (CHO) cells as a suitable eucaryotic expression system. In pEFdhfr (Fig. 3), the
expression of the construct of interest is driven by the promotor of the human elongation
factor alpha. This promotor is known to be a very strong promotor in virtually all eukaryotic
cells, thereby making this expression system a powerful tool for high protein expression
without limitations regarding the selected eukaryotic host cell line49.  The construct of interest
is cloned into the multiple cloning site (MCS) using one or more of the restriction sites
encoded in the MCS (EcoR1, Xba1, Sma1, Sal1). The expression of the construct of interest is
linked to the expression of the selection marker dihydrofolate reductase (DHFR) via the
internal ribosomal entry site (IRES). This arrangement assures that almost all stably
transfected cells will express the construct, as both genes depend on the promotor of EFα. A
strong polyadenylation signal for both genes is provided by the SV40 polyadenylation site,
and the pUC18 backbone of the plasmid provides a well-characterized plasmid backbone with
ampicillin resistance for cloning purposes. This vector was used for the expression of the
constructs encoding the two fusion proteins MOG-Fc and MOGxCD3.
pEFdhfr
5822 bp
IRES (Pol)
SV40 Poly A
VA1
pUC18 backbone (Amp)
MCS
hEF-A Promotor
WT-dhfr
Fig. 3. Expression vector pEF-dhfr for transfection of dhfr-deficient chinese hamster ovary cells (CHO).
MCS: multiple cloning site. IRES: internal ribosomal entry site. Dhfr: dehydrofolate reductase. SV40 Poly A:
simian virus 40 polyadenylation sequence. PUC18: ampicillin resistance. HEF-A promotor: promotor of
human elongation factor alpha
MOG-Fc construct
1173 bp
MOG-ex hu IgG1: hinge-CH2-CH3
MOG-leader
MOGxCD3 construct
1241 bp
anti-CD3 scFv His-taglinkerMOG-ex
MOG leader
Fig. 4. Generation of fusion protein constructs. A. Domain arrangement of MOG-Fc construct. B. Domain
arrangement of MOGxCD3 construct. MOG-ex: extracellular domain of human myelin oligodendrocyte
glycoprotein.
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Fig. 5. Structure of fusion proteins A. Design of MOG-Fc. The constant CH3 and CH2 domains of human
IgG1 (Hu IgG1) (open boxes), including the hinge region with two disulfide bonds, were fused to the
extracellular domain of human myelin oligodendrocyte glycoprotein (Hu MOG) (filled boxes). B. Design of
MOGxCD3. The extracellular domain of human MOG was connected to a C-terminally attached scFv
antibody directed against the ε chain of the human CD3 complex. N, N termini; C, C termini.
5.1.2. Design and characterization of MOG-Fc
The N-terminal 154 amino acids of the extracellular domain of human pro-MOG were fused
to the C-terminal 233 amino acids of human IgG1 encompassing the hinge, CH2 and CH3
domains (see Fig. 4 for domain arrangement). The basic architecture of the fusion protein is
shown in Figure 5A. Placing the fusion junction at the flexible hinge is known to facilitate
proper folding of domains and helps to preserve the function of both parts of the molecule58;59.
The pEFdhfr expression vector for MOG-Fc was constructed as described in the experimental
protocol. Chinese hamster ovary (CHO) cells were transfected with the vector and selected for
stable expression of the selection marker dhfr for a period of approximately two months.
Glycosylation patterns of proteins expressed in CHO cells are very similar to those of human
origin, which provides for maintenance of binding capacity to B cells as well as effector cells
and also reduces the likelihood of immune responses to the fusion protein itself. Moreover, Fc
fusion proteins can be expressed in CHO cells in much the same manner and efficacy as
whole immunoglobulins. Purification of the molecule can be then be performed in a single-
step protein A affinity chromatography. The ease of this type of purification, together with
efficient mammalian cell expression, are significant advantages of such a bispecific Ig-
chimera containing the Fc region over other fusion protein formats.
After completion of the selection procedure, stably transfected cells were used to seed a panel
of 500 ml cell-culture roller bottles. It was discovered that culture systems allowing adherent
growth of CHO cells (NalgeNunc International) produced the most consistent results. CHO
cells were cultured 3 days post-confluency, which amounted to approximately 8-10 days in
total culture time. MOG-Fc was purified from cell culture supernatant using a single protein A
affinity chromatography step. Average yield was on the order of 5 – 10 mg of secreted
recombinant protein per liter of cell-culture supernatant. All of the MOG-Fc fusion protein
purified from culture supernatant appeared to be in a dimerized form, as was evident upon
SDS-PAGE analysis (Fig. 6, left panel) and by Western blotting using an anti-MOG
monoclonal antibody (Fig. 6, right panel). Under reducing conditions, the affinity-purified
MOG-Fc had an apparent molecular weight of 49 kDa (Figs. 3, lanes labeled +DTT), which is
in accordance with the calculated molecular weight of 42 kDa and an expected complex-type
N-glycosylation. A single band with an apparent molecular weight of 98 kDa was seen upon
SDS-PAGE in the absence of reducing agent. Under these conditions, no monomeric MOG-
Fc was detectable by SDS-PAGE or Western blotting (Figs. 6).
The  integrity of the MOG-Fc protein was further confirmed in a sandwich ELISA using the
anti-MOG monoclonal antibody 8.18-C5 for capturing and an alkaline phosphatase (AP)-
conjugated anti-human-IgG antibody for subsequent detection (Fig. 7). Titration of the
purified MOG-Fc protein resulted in a dose-dependent signal, showing that both antigen
(MOG) as well as effector (IgG1-Fc) domains of the recombinant protein were present. Also,
binding to the anti-MOG monoclonal antibody 8.18-C5 provided evidence that the B-cell
targeting domain at the N-terminus of the fusion protein was correctly folded and capable of
binding MOG-reactive immunoglobulin, as would be encountered in membrane-bound form
on MOG-reactive B cells.
Taken together, size analysis by SDS-PAGE, Western blotting and binding to anti-MOG and
anti-human Fc antibodies in ELISA suggested that MOG-Fc of the correct size and
antigenicity was produced by CHO cells. Thus, all structural requirements of the MOG-Fc
fusion protein were met.
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cells and affinity-purified by protein A sepharose chromatography. Left: SDS-PAGE analysis of purified
MOG-Fc in the absence (lane 1) and presence (lane 2) of the reducing agent diothiothreitol (DTT). Right:
Western blot analysis of MOG-Fc in the absence (lane 1) and presence (lane 2) of DTT. After transfer of
MOG-Fc from SDS gel to nitrocellulose filter, MOG-Fc was detected by the MOG-specific monoclonal
antibody 8.18-C5 and an AP-conjugated secondary goat-anti-mouse antibody. The position of molecular
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Fig. 7. Detection of MOG-Fc fusion protein in ELISA. ELISA plates were coated with anti-MOG antibody
8.18-C5 to capture the fusion protein by its MOG domain. Bound MOG-Fc fusion protein was detected with
an AP-conjugated anti-human Fc antibody.
5.1.3. Design and characterization of MOGxCD3
For the construction of a MOG fusion protein with specificity for human T cells, expression
vector pEF-dhfr was used. The construct consisted of the MOG extracellular domain at the N-
terminus fused to the heavy chain variable region of an anti-human CD3 epsilon-specific Fv
fragment (see Fig. 4, 5)49. A flexible glycine-serine linker with 15 amino acids in length was
used to connect the two anti-CD3 VH and VL variable domains. A stretch of 6 histidines was
fused at the outer C-terminus to allow affinity purification over nickel-chelating columns.
Following stable transfection into dhfr-deficient CHO cells, the secreted protein was purified
by 3-step chromatography, consisting of cation exchange, metal chelate chromatography and
gel filtration. Identity and size of the purified recombinant protein were investigated via SDS-
PAGE analysis followed by Western blotting.
After gel filtration, a single band was visible in SDS-PAGE, corresponding to the predicted
size of the MOGxCD3 fusion protein (Fig. 8A, lane 5). Western blotting with 8.18-C5 anti-
MOG monoclonal antibody revealed a single band with MOG reactivity (Fig. 8B) of the size
observed in SDS-PAGE. Thus, both protein size and anti-MOG immunoreactivity were as
expected.
In order to test whether both the MOG targeting moiety and the CD3 effector domain were
present in the MOGxCD3 fusion protein, an ELISA was established using anti-MOG
monoclonal antibody for capture followed by detection by an anti-Fv antibody specific for the
anti-CD3 scFv. As shown in Fig. 9, incubation with MOGxCD3 resulted in a dose-dependent
signal. Thus, MOGxCD3 was produced as an intact molecule consisting of both effector and
targeting domains, and therefore had the potential to bridge MOG-reactive B-cell receptors
and human T cells via CD3 epsilon. Furthermore, the binding of 8.18-C5 anti-MOG antibody
to the fusion protein indicated that the MOG targeting moiety was correctly folded, since
8.18-C5 detects a conformation-dependent epitope of the MOG extracellular domain52.
In conclusion, biochemical analysis revealed that two fusion proteins of the desired size and
immunoreactivity were generated. These two proteins met all requirements they were
designed for: MOG reactivity was found with both MOG-Fc as well as MOGxCD3,
indicating that the MOG extracellular domain was correctly folded. Both proteins were
readily secreted into the cell culture supernatant, which shows that the MOG-specific leader
sequence can efficiently direct export of MOG antibody fusion proteins to the extracellular
compartment. MOG-Fc was produced as a disulfide-linked dimer, whereas MOGxCD3 was
detected solely as a monomeric protein upon gel filtration.
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BAFig. 8. Design, expression, purification and characterization of MOGxCD3. MOGxCD3 was expressed in
CHO cells and affinity-purified by 3-step chromatography. A. 5 Gel filtration peaks are shown, separated by
SDS-PAGE and analyzed by Coomassie blue staining. Peak number 5 contains monomeric MOGxCD3
protein of a molecular mass of approximately 47kDa B. After transfer of MOGxCD3 from SDS gel to
nitrocellulose filter, MOGxCD3 was detected by the MOG-specific monoclonal antibody 8.18-C5 and an
AP-conjugated secondary goat-anti-mouse antibody. The position of molecular weight standards is shown on
the left and their size given as kilo Dalton (kDa).
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Fig. 9. Detection of MOGxCD3 fusion protein in ELISA. ELISA plates were coated with anti-MOG
antibody 8.18-C5 to capture the fusion protein by its MOG domain. Bound MOG-Fc fusion protein was
detected with  an AP-labelled chicken-anti-scFv polyclonal antibody.
5.2. Binding of MOG fusion proteins to effector cells
Biochemical analysis showed that the structural requirements were fulfilled by both
recombinant proteins. Furthermore, ELISA data proved that the MOG domain was correctly
folded and functionally intact, and that proteins containing both effector and MOG domain on
a single polypeptide chain were generated. The ability of the Fc part in MOG-Fc to bind to
Fc-receptor positive cells, as well as the capability of the anti-CD3 scFv in MOGxCD3 to
bind to human T cells was examined in the following experiments.
5.2.1. Binding of MOG-Fc to Fc receptor-positive cell line
The murine monocyte-macrophage cell line p388.D1 was employed as FcR-positive cell
line53. The p388.D1 cells were incubated with various dilutions of the MOG-Fc protein.
Binding of the Fc fusion protein was investigated in FACS analysis via FITC-labeled anti-
human Fcγ antibody. As shown in Fig. 10, bound MOG-Fc was detected in a dose-dependent
manner. MFI values observed for MOG-Fc were similar to those obtained with another
human IgG1 serving as isotype control (not shown). The Fc effector domain of the fusion
protein was intact, properly dimerized and thus capable of binding to FcR+ cells. This
suggested that the MOG-Fc protein was truly of a bispecific nature, capable of binding to both
effector as well as target cells.
Fig. 10. Binding of MOG-Fc to a murine macrophage cell line. The monocyte/macrophage cell line p388.D1
expressing murine Fc receptors was incubated with MOG-Fc. Bound MOG-Fc was detected via FITC-
labeled anti-human Fcγ antibody by flow cytometry (left panel). Binding was quantitated and is expressed as
mean fluorescence intensity (MFI) (right panel).
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5.2.2. Binding of MOGxCD3 to primary human T cells
Single-chain antibody fragments can suffer a complete loss in binding activity when fused to
other protein domains. This is due to the fact that the unnaturally linked heavy and light chain
variable domains have to firmly assemble to form a binding groove for their respective
antigen. In a complete antibody, the constant domains of the Fab part serve dimerization via a
disulfide bridge in the CH1 region, allowing correct assembly of the separate variable domains
from heavy and light chains.
To investigate whether the MOGxCD3 construct was still able to bind to CD3ε on human T
cells, a FACS-based binding assay was used. Human CD3-positive cells were isolated from
buffy coats as described in the material and methods section. Following incubation with
varying concentrations of the MOGxCD3 fusion protein, recombinant protein bound to CD3-
positive cells was detected with anti-MOG monoclonal antibody. FACS analysis revealed a
dose-dependent signal at protein concentrations between 4 and 100 µg/ ml (Fig. 11). This
result was not necessarily expected, since fusion partners other than scFvs have never been
investigated with this C-terminal anti-CD3 antibody fragment. Thus, the MOGxCD3 protein
was able to bind to human T cells as well as the anti-MOG B-cell receptor, a prerequisite for
receptor bridging between T cells and autoreactive B cells.
Taken together, in vitro analysis indicated that MOG-Fc and MOGxCD3 fusion proteins of
the correct size and structure were generated with the desired binding properties of the MOG
targeting, Fcγ- as well as anti-CD3 effector domains. These proteins had the potential to
bridge the receptors of autoreactive B cells with those of effector cells, which may lead to re-
directed lysis of the putative target B cell. Consequently, a test for functional activity was
developed in order to investigate the biological properties of the generated fusion proteins.
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Fig. 11. Binding of MOGxCD3 to human T cells. Fusion protein was incubated with human CD3-positive
PBMCs, and MOGxCD3 bound to T cells was detected with monoclonal anti-MOG antibody followed by
FITC-labelled anti-mouse IgG1 antibody. Mean fluorescence intensity values (MFI) obtained in FACS
analysis are shown.
5.3. Assessment of in vitro cytotoxicity
To test whether the potential crosslinking of target and effector cells by MOG fusion proteins
is leading to elimination of MOG-reactive target cells, an in vitro FACS-based cytotoxicity
assay54;55 was developed (illustrated in Fig. 13). A major challenge of the assay was the
generation of a suitable target cell line. Primary B cells from anti-MOG transgenic animals
did not tolerate the assay conditions and went into apoptosis within hours post-isolation (data
not shown). Due to the extremely low abundance of anti-MOG B cells in humans, patient
material was not an option either. A solution was found: 8.18-C5 hybridoma cells were
cultured in serum-free medium for a period of 4-5 months. Long-term culture appeared to
induce the expression of high levels of cell-surface bound anti-MOG antibody (Fig. 12). This
may be due to a shift in mRNA processing leading to a transcript which contains the MC
exons coding for the transmembrane region of cell surface immunoglobulin.
As seen upon FACS analysis (Fig. 12A), adaptation to serum-free medium of 8.18-C5
hybridoma cells that normally secrete anti-MOG monoclonal antibody resulted in an
expression of cell surface-associated murine IgG. Such hybridoma cells were capable of
binding recombinant MOG on their cell surface (Fig. 12B). Thus, a stable target cell line was
generated that expressed anti-MOG binding specificity on the surface. This cell line was used
in conjunction with purified human PBMCs as effector cells to examine antibody-mediated
cellular cytotoxicity.
AB
Fig. 12. Flow cytometric characterization of a hybridoma line expressing MOG-reactive surface IgG.  A.
Surface expression of IgG on 8.18-C5 hybridoma cells. Hybridoma cells were cultivated in serum-free medium
for 4-5 months, and cell-surface muIgG1 expression was examined with FITC-labeled goat-anti-muIgG1
antibody using flow cytometry. B. rMOG binding to the 8.18-C5 hybridoma line. Binding was examined with
biotinylated rMOG followed by staining with streptavidin-PE. Controls show staining with the secondary
labeling reagents alone.
5.3.1. Investigation of cytotoxicity mediated by MOG-Fc
A FACS-based assay was developed to examine antibody-dependent cellular cytotoxicity
mediated by the MOG-Fc fusion protein. This assay was based upon 1) discrimination of live
and dead cells by propidium iodide (PI) and 2) identification of target cells via a specific
marker (illustrated in Fig. 13). PI is a dye that stains cells having lost membrane integrity. In
contrast to other systems, such as annexinV labeling, which is a marker for early apoptotic
events, PI stains both apoptotic and necrotic cellular populations at a relatively advanced
stage of cell death60-63. As a target cell marker, an antibody specific for mouse IgG was
chosen. This assay system turned out to produce the most consistent results. Other variations
of the assay, such as pre-labeling of target cells with the vital dye calcein, proved to be
unreliable (data not shown). This was due to the fact that the anti-MOG target cell line was
propagated in serum-free medium and did not tolerate the calcein labeling procedure. Uptake
of labeled cells by macrophages, which can result in false-positive stainings, is a problem that
was also occasionally encountered in this type of assay. Plotting PI on the y-axis versus anti-
mouse IgG on the x-axis of a FACS dot plot, was chosen as the preferred discrimination
between target and effector cells.
blood
PBMCs
T-cells
target cells
MOG-Fc
MOGxCD3
PI
spec. marker
96-well tissue
culture plateFig. 13. FACS-based assay for the investigation of antibody-dependent cellular cytotoxicity
(ADCC) mediated through bispecific fusion proteins. Primary blood mononuclear cells (PBMC)
were extracted from buffy coats obtained from human donors. For investigation of cytotoxicity
mediated by anti-CD3 fusion proteins, T cells were further enriched and used as effectors. Primary
effector cells and target cells were incubated in 96-well tissue culture plates for the duration of the
assay. FACS analysis (lower right) was carried out with a specific target cell marker stained against
propidium iodide to discriminate between live and dead target cells.
Incubation of human PBMC as effectors and 8.18-C5 target cells at a ratio of 10:1 in the
presence of MOG-Fc resulted in a complete elimination of anti-MOG target cells, as seen by
the disappearance of propidium iodide-negative, anti-murine IgG-positive cells in the
presence of human PBMC (Fig. 14A). No significant target cell lysis was observed in the
absence of PBMCs or fusion protein (Fig. 14B). A dose-response analysis showed that half-
maximal efficacy of specific target cell lysis occurred at a concentration below 100 ng/ml
MOG-Fc (Fig. 14C). Complete elimination of target cells was achieved at an optimal dose of
10 µg/ml, while further increases in protein concentration up to 100 µg/ml resulted in a
decrease in specific toxicity (not shown).  propidium iodide-negative, anti-murine Iin the
presence of human PBM
The specificity of MOG-Fc-mediated cell lysis in the assay was investigated by using both
unrelated human IgG1 and a mouse B-cell line expressing unrelated IgG on its surface. (Figs.
14D and E). The EpCAM antigen-specific recombinant human IgG151 that can bind to human
effector cells via its Fc part, but not to MOG-specific immunoglobulin on hybridoma cells,
did not lead to significant redirected lysis of 8.18-C5 cells (Fig. 14D, bar 2). Likewise, the
mouse B cell line TIB-208, expressing cell-surface IgG of non-MOG specificity, was not
sensitive to MOG-Fc mediated lysis (Fig. 14E, bar 2). The assay was repeated 6 times.
Maximum efficacy was dependent on PBMC donor and ranged from complete elimination
(>98% specific lysis in 3 independent experiments) down to 44% at optimal dose. Anti-mouse
IgG1 staining was not inhibited by the presence of the fusion protein.
In conclusion, the data obtained with this FACS-based ADCC assay show that the MOG-Fc
fusion protein was indeed able to re-direct primary human effector cells to kill anti-MOG
positive hybridoma cells. Re-directed lysis was observed in a specific dependence on the
target BCR and fusion protein specificity. The outcome of the experiment was unpredictable,
since coupling of B cells and FcγR+ effectors through an Fc fusion protein may lead to a cell-
to-cell distance (see Fig. 2C as an illustration) that is larger than with antibodies against
smaller cell-surface molecules, such as CD20. It is conceivable that a putative large distance
may have prevented the effective engagement and subsequent triggering of FcγR+ effector
cells.
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Fig. 14. Cytotoxic activity of MOG-Fc. 8.18-C5 target cells were incubated with human PBMCs and serial
dilutions of MOG-Fc protein in RPMI/10% FCS. Incubation was performed for 16 h at 37°C/5% CO2 . After
incubation, target cells were labeled with anti-muIgG1 antibody (mIgG) and analyzed for viability through
propidium iodide (PI) staining. A. Flow cytometric detection of target cell lysis. FACS scans from untreated
and MOG-Fc-treated target cells on a background of PBMCs is shown. The gate used for quantitation of
target cell elimination is indicated. B. Dependence of target cell elimination on both PBMC and MOG-Fc. As
indicated, the assay was performed for 16 h in the absence or presence of PBMCs (ET-ratio 10:1) and 10
µg/ml MOG-Fc. C. Dose response of the cytotoxic effect of MOG-Fc. The assay was performed at the
indicated concentrations of MOG-Fc for 16 h in the presence of PBMCs (E:T ratio = 10:1). Viable muIgG-
positive target cells were counted and normalized to percentage of viable target cells in the control (see
Experimental Protocol). Data are representative of 3 experiments with similar results. D. The effect of a non-
specific human IgG1. Column 1, incubation of PBMCs and target cells in the absence of isotype control and
MOG-Fc. Column 2, the effect of a recombinant human IgG1 (isotype control). Column 3, the effect of
MOG-Fc under identical assay consitions. E. The effect of MOG-Fc on an unrelated murine cell line. Mouse
B cell line TIB-208 is expressing cell surface IgG1 of non-MOG specificity. Column 1, spontaneous lysis of
TIB-208 cells in the presence of human PBMC. Column 2, the effect of MOG-Fc (10 µg/ml) on the viability
of TIB-208 cells. Column 3, the effect of MOG-Fc (10 µg/ml) on hybridoma line 8.18-C5 under identical
assay conditions. Error bars indicate S.D. values of triplicates.
5.3.2. Investigation of cytotoxicity mediated by MOGxCD3
The cytotoxicity mediated by the MOGxCD3 fusion protein was investigated in the FACS-
based assay also used for the Fc fusion protein. The only difference was that freshly isolated
human T cells rather than whole PBMCs were used as effectors. FACS analysis revealed
disappearance of PI-negative, mouse-IgG positive target cells with increasing concentrations
of the MOGxCD3 protein (Fig. 15A). This dose-response analysis showed half-maximal lysis
at a concentration of approximately 100 ng/ ml (Fig. 15A). Maximal redirected lysis was
observed at an optimal concentration of 1 µg/ ml, translating into 80% specific toxicity after
incubation for 16 h at 37°C/ 5% CO2. Thus, MOGxCD3 was produced as an active molecule
capable of re-directing primary human T cells to kill anti-MOG positive target cells.
The specifity of cell-mediated toxicity was investigated as shown in Fig. 15B. MOGxCD3-
mediated lysis was dependent on the presence of effector T cells (Fig. 15B, bar 2).
Spontaneous lysis, measured after separate incubation of both effector and target cell
populations for the duration of the assay, is shown in the last bar; here, cells were added
together just prior to FACS analysis. Furthermore, incubation of cells at an effector-to-target
(E:T) cell ratio of 5:1, instead of the standard 10:1 ratio, resultet in a shift of EC50 of
approximately a factor of 10, providing further evidence that MOGxCD3-mediated lysis is
effector-cell dependent (Fig. 16).
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Fig. 15. Cytotoxic activity of MOGxCD3 fusion protein. FACS-based assay was performed. 8.18-C5 target
cells were incubated with human CD3+ PBMCs and serial dilutions of the MOGxCD3 protein. Incubation
was performed for 16h at 37°C/ 5% CO2. After incubation, target cells were labelled with anti-IgG1 antibody
and analyzed for viability through counterstaining with propidium iodide (PI). Viable murine IgG1+ cells
were counted and expressed as percentage of viable target cells in control (see materials and methods). A.
Dose-response analysis. B. Specificity of lysis.
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Fig. 16. Cytotoxic activity of MOGxCD3 is dependent on ratio of effector to target cells (E:T-ratio). Assay
was performed as described for Fig. 11 with varying concentrations of effector cells and a constant number of
8.18-C5 target cells. Black bars: E:T-ratio 10:1. White bars: E:T-ratio 5:1.
In summary, these data show that MOGxCD3 exhibited cytotoxic activity against anti-MOG
positive target cells. This in-vitro cytotoxicity was effector-cell dependent and specifically
mediated by the fusion protein. Thus, human T cells could be re-directed and triggered to kill
anti-MOG positive target cells by the novel MOGxCD3 antibody fusion protein.
5.4. Investigation of MOG-Fc in vivo using a transgenic mouse model
The effect of the MOG-Fc fusion protein on natural B cells was further investigated using the
anti-MOG transgenic TH mouse model (illustrated in Fig. 1)11. Since human Fcγ1 is known to
interact with murine Fc receptors, these studies were feasible42;64. This is in contrast to the
MOGxCD3 molecule49, which is specific for human CD3 only and does not cross-react with
the mouse TCR complex. Therefore, the following sections will deal exclusively with the
characterization of the MOG-Fc fusion protein.
5.4.1. Cell binding activity
Binding of MOG-Fc to primary MOG-reactive B cells as well as primary effector cells was
investigated using splenocytes from anti-MOG transgenic and wild-type mice (Fig. 16A). In
these transgenic mice (designated TH), the endogenous heavy chain-J region has been
replaced by the rearranged 8.18-C5 anti-MOG VDJ segment using knock-in technology (see
Fig. 1)11;65. As a result, almost all B cells of transgenic mice express the MOG-specific heavy
chain in combination with endogenous light chains.
It was observed in FACS analysis that >90% of all IgM-positive splenocytes from the TH
knock-in mice (Fig. 17A, lower panel in bold) but not of control littermate mice (Fig. 17A,
upper panel) did bind recombinant MOG-Fc. Approximately one third of IgM-positive B cells
in TH mice bound MOG-Fc with high intensity while the remaining two thirds bound MOG-
Fc with low intensity (Fig. 17A, lower panel). This binding pattern is reminiscent of the one
reported using biotinylated, bacterially produced, recombinant rat MOG (rMOG)11;66. In this
report, however, two thirds of the TH B cells did not bind rMOG at all or only poorly, and
only one third of B cells bound rMOG with a broad range of intensities. Such differences are
likely due to an intrinsically higher affinity of TH B cells to MOG-Fc which, in contrast to the
bacterially generated rMOG, is dimeric, properly folded, N-glycosylated and has not
undergone biotinylation.
Binding of MOG-Fc to wildtype splenocytes was also investigated. The upper panels of
Figure 17B and 17C show FACS staining of wild-type splenocytes in the absence of MOG-Fc
fusion protein. In the lower panel, wild-type splenocytes were incubated with MOG-Fc, and
identical FACS stainings as in the upper panel were performed. As seen in panel 17B, MOG-
Fc did bind to the Mac1high (CD11b) population, indicating a preferential binding to
macrophages and myeloid CD8+ DCs67;68. No binding of MOG-Fc to CD5+ T cells could be
detected, underscoring the selectivity for FcγR+ cells. Anti-MOG (8.18-C5) positive cells in
the lower quadrants most probably represented B cells binding the protein through their
inhibitory Fc receptor FcγRII-B1. In contrast to panel A, stainings in the lower quadrants of
Fig. 17B and 17C were performed at room temperature (see materials and methods).
In conclusion, these data show specific binding of MOG-Fc to both MOG-reactive B cells as
well as Fcγ-receptor positive immune effector cells on primary mouse splenocytes.
A B C
IgM
huFc
Mac1
8.18-C5
CD5
8.18-C5
Fig. 17. Flow cytometric analysis of cell binding properties of MOG-Fc. A. Binding of MOG-Fc to B cells of
Ig-MOG transgenic TH mice (bolded box). Splenocytes from wt (upper panel) and TH mice (lower panel,
bold) were prepared and incubated with MOG-Fc. MOG-Fc bound to IgM-positive cells was detected by
FITC-labeled human Fcγ-specific antibody (huFc). B, C. Binding of MOG-Fc to Mac-1- and CD5-positive, wt
mouse splenocytes. Single-cell suspensions of splenocytes were prepared. Cells were incubated with 50 µg/ml
MOG-Fc protein (lower panel) or PBS (upper panel). Cell-bound MOG-Fc was detected with biotinylated,
monoclonal α−MOG antibody 8.18-C5, followed by counterstaining with streptavidin-FITC, and Mac1-
phycoerythrin (PE) or CD5-PE. Low-avidity binding to Mac1 and CD5 negative subpopulation in the lower
panel is due to staining protocol.
5.4.2. In vivo effect of MOG-reactive B cells in transgenic and wild-type mice
5.4.2.1. Antibody responses in mice treated with MOG-Fc
It was the aim of this study to devise new strategies aimed at targeting autoreactive B cells in
the MOG-Ig model system with the potential to be used as therapeutics in autoimmune
disease. Two key questions had to be answered:
 I. Does treatment with the fusion protein lead to antibodies against the two functional
domains of the protein?
 II. Can one detect a B-cell depletion by MOG-Fc treatment in a "worst-case scenario"
where high titers of autoreactive antibodies are present and constantly replenished?
For question I., the answer was quite predictable. Indeed, human Fc is immunogenic in mice
and led to formation of anti-Fc antibodies. As shown in figure 18A, wild-type mice develop
anti-human Fc-specific IgG after treatment with the MOG-Fc protein. On the same note,
MOG is regarded as being essentially 'foreign' by the peripheral immune system due to its
CNS restriction66;69. Consequently, both anti-Fc and anti-MOG IgG antibodies were detected
in wild-type mice treated with MOG-Fc fusion protein 22 days post-treatment (Fig. 18A, B).
Concerning the second question, the outcome is not easily foreseeable. Would the protein ever
reach its target B cells in the presence of substantial anti-MOG Ig in the serum11? Would
application of the protein lead to pathogenic phenomena, such as immune-complex deposition
and renal failure, or shock syndromes? Can a depletion of MOG-reactive B cells be detected
at all?
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Fig. 18. Serum antibody titers in response to treatment with MOG-Fc. Mean values for 3-5 animals are
shown. A. IgG response against human IgG1-Fc in wild-type (wt) mice. A1. Background signal of each
individual sera sample against BSA was taken into account to normalize ELISA values (signal-to-
background ratio). Black bars: mice treated with the fusion protein on day 1, 3 and 5. White bars:
Untreated control animals. A2. Change of IgG response against human Fc in wt mice. Difference
between values for treated vs. untreated control animals are plottet on the y-axis, obtained as illustrated in
Fig. A1. B. Change in anti-MOG IgG response in wt mice. C, D. Response of TH mice post treatment
with MOG-Fc. C. IgG titer against human Fc in MOG-Ig mice. D. Change in IgG titer against MOG in
TH mice after treatment with the MOG-Fc fusion protein.
In fact, treatment of TH mice led to anti-human Fc titers with a kinetic profile comparable to
that induced in wild-type animals (Fig. 18C). Twenty-two days post-treatment, TH mice
developed anti-human Fc IgG titers (Fig. 18C). Surprisingly, anti-MOG IgG was markedly
reduced in TH mice followed for 22 days after treatment (Fig. 18D). This reduction was most
pronounced at day 15 post-treatment but still prominent throughout the 22-day observation
period of the experiment. Evidently, treatment with MOG-Fc induced an antibody response
against human Fc while, at the same time, leading to long-term reduction of anti-MOG
antibody titers in TH mice. This result suggested an effect that could not simply be mediated
by short-term adsorption of anti-MOG immunoglobulin and subsequent clearance of immune
complexes. Thus, the cytotoxic effect of MOG-Fc on MOG-specific B cells was further
investigated.
5.4.2.2. Ex vivo cytotoxic activity of MOG-Fc
To assess whether MOG-Fc can also eliminate natural B cells expressing MOG-reactive cell-
surface immunoglobulin in a physiological environment, splenocytes from anti-MOG
transgenic TH mice were isolated and tested in an ex vivo assay system. A special
polypropylene cell culture system was established that allowed the isolated primary
splenocytes to maintain viability for periods greater than 48 hours in a small medium volume
of 250 µl. In addition, recovery of lymphocytes was almost quantitative after the assay period,
since the polypropylene vials did not allow macrophages or monocytes to attach to the plastic
surface.
Transgenic splenocytes were prepared and incubated with 10 µg/ml of the fusion protein for
16 hours. The endogenous FcγR-bearing cells served as effectors. FACS analysis documented
a highly significant depletion of B cells, as defined by antibodies specific for the allotype-
specific B cell marker IgMa, for IgD and for CD19 (Fig. 19). For all three markers, B cell
depletion reached an order of 70%. The 10% increase in the percentage of Thy1+ T-
lymphocytes mirrored the decrease in MOG-specific B cells, representing about 10% of total
live lymphocytes in the samples (Fig. 19).
Thus, the MOG-Fc protein was able to trigger mouse endogenous effector cells to specifically
kill syngenic, MOG-reactive B cells in ex vivo splenocyte cultures from TH mice.
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Fig. 19. The effect of MOG-Fc on TH splenocytes ex vivo. Single cell suspensions of spleens from Ig-
MOG transgenic TH mice were prepared. Splenocytes were cultured in the absence (dark columns) or
presence (white columns) of MOG-Fc (10 µg/ml). After incubation, the B cell population was analyzed by
flow cytometry using antibodies against the B cell markers IgM, IgD and CD19 and, as non-B cell marker,
anti-Thy1. The frequency of cell populations is expressed as percentage of total live cells within the
lymphocyte gate. Error bars represent S.D. values of triplicates.
5.4.2.3. Effect on the B-cell population in TH mice
Having proven that MOG-Fc can deplete autoreactive B cells both in vitro and also ex vivo,
the biological properties of the fusion protein were investigated in the relevant animal model.
The cytotoxic efficacy of MOG-Fc was tested in vivo using the anti-MOG transgenic TH
mouse. One hundred µg of MOG-Fc was administered intraperitoneally on days 1 and 3, and
peripheral blood B lymphocyte counts were determined by FACS analysis one day post
treatment. In spite of the fact that MOG-reactive B cells are generated in the bone marrow of
mice on the order of 107 cells/ day (Antonio Iglesias, unpublished observation), which
continuously replenishes eliminated B lymphocytes, it was found that MOG-Fc was efficient
in depleting IgM-positive B cells in the fraction that strongly reacted with MOG (Fig. 20A,
upper panel). MOG-Fc was still bound to B cells 24 h post-treatment (Fig. 20B), as detected
by anti-human Fcγ staining of isolated B220-positive blood lymphocytes.
The percentage of MOGhigh B-cells decreased with statistical significance from 45% in control
to less than 30% on day 4 after the first treatment (Fig. 20B). Since the number of B220-
positive B cells was decreased to the same extent as the number of IgM-positive B cells (not
shown), it is concluded that the reduction of B cells, as measured by flow cytometry, was due
to depletion of cells and not associated with down-modulation of the B-cell receptor.
In summary, MOG-Fc was able to deplete autoreactive B cells in an in vivo model system.
Remarkably, this result was observed in the presence of extremely high anti-MOG antibody
titers and of an almost exclusively MOG-Ig positive B cell population.
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Fig. 20. Effect of MOG-Fc treatment on
MOG-Ig tg mice. TH mice were left
untreated (Control) or treated i.p. with 100
µg of MOG-Fc protein on days 1 and 3. A.
Flow cytometric analysis of B cells from
MOG-Fc-treated TH mice. Upper panel,
the effect of MOG-Fc on IgMa-positive,
rMOG-reactive B cells. Lower panel,
analysis of MOG-Fc binding to B220-
positive B cells as detected by an anti-
human Fcγ antibody. Peripheral blood
lymphocytes (PBLs) were prepared 1 day
post-treatment and their MOGhigh B-cell
population was analyzed as indicated.
Five MOG-Fc-treated and three control
animals were analyzed. Representative
results are shown. B. The effect of MOG-
Fc on the MOGhigh B-cell population in
TH mice. FACS data from five animals
were quantitated and are shown as
percentage of total B220+ cells. Bars give
S.D. values.
5.4.2.4. Effect  of MOG-Fc on autoreactive B cells and antibody titers in a transfer
model
The normal B-cell population in mice is naturally dominated by naive, IgM+, IgD+ B
lymphocytes. In MOG-Ig transgenic TH mice, B cell development follows a normal path66.
Therefore, B cell depletion can be observed for the naive B-cell population only. In an
autoimmune situation, however, the pathogenic cellular compartment that needs to be
addressed is not that of the naive B cells, which has never encountered antigen, but it is the
actively switching, proliferating B-cell blast compartment. A direct measurement of anti-
MOG IgG secreted by these activated B lymphocytes, and by plasma cells, was of special
interest in this context, since a marked decrease in anti-MOG IgG was observed in TH mice
treated with the fusion protein. On the same note, significant changes in MOG-specific IgM
titers were never encountered in TH mice. Therefore, the effect of MOG-Fc treatment on an
activated B-cell population in the absence of an endogenous B-cell pool with MOG specificity
was examined.
In TH mice, the number of MOG-reactive B cells is much higher than what the MOG-Fc
protein would encounter in an autoimmune situation in non-transgenic mice. Nonetheless, TH
mice treated with MOG-Fc showed a significant reduction in their MOG-reactive B-cell
population. However, this system is rather artificial due to constant replenishment of MOG-
reactive B cells from the bone marrow in high number and does not allow a fair comparison to
autoimmune conditions encountered in humans, where few autoreactive B cells are present
among a large background of endogenous, non-reactive B lymphocytes. To investigate a more
natural situation, the capacity of MOG-Fc to deplete defined numbers of MOG-specific B
cells adoptively transferred from TH mice into syngenic wild type mice was analyzed.
C57BL/6 mice were first injected i.v. each with 1.6 x 107 LPS-stimulated, purified TH B-cells
and then, on days 1, 2 and 3 after transfer, individual groups of transferred mice received 100
µg of MOG-Fc i.p., control human IgG1 or PBS. The use of LPS-stimulated, instead of
resting, B cells permitted the assessment of the effect of MOG-Fc on surface Ig+ blast cells in
the presence of secreted anti-MOG Abs, a situation more likely to reflect an ongoing
autoimmune response in need of therapy. As shown in Fig. 21B, six days after B cell transfer,
recipient mice treated with PBS or control human IgG1 Ab51 consistently accumulated in their
peripheral blood about 3% of MOG-binding, IgG+ B cells, as well as high titers of MOG-
specific IgM and IgG (Fig. 21A). In contrast, mice treated with MOG-Fc showed a strong
though not complete depletion of both MOG-binding B cells and Abs (Fig. 21B, black
column). MOG-Fc was detectable in serum at an average concentration of 21 µg/ml 3 days
after treatment, while serum titers were below detection limit by day 10 (not shown). This is a
remarkable result, since anti-MOG IgG was found to be reduced throughout the 22-day
observation period in TH mice (Fig. 18D). This result shows that the reduction in autoreactive
immunoglobulin titer in both the TH but also the wild-type transfer model system was caused
by depletion of B cells, and not mainly through passive absorption and short-term clearance of
immune complexes.
Interestingly, no pathological side effects were observed in any of the treated animals (both
TH and transferred wild-type groups) followed for 2 months post-treatment. This is an
interesting finding, since both MOG-Fc and MOG-specific antibodies were present at high
titers in the animals that had received the fusion protein.
In final conclusion, these data demonstrate that the MOG-Fc antibody fusion protein exhibited
the desired cytotoxic properties against autoreactive B cells in all systems investigated. In
vitro analysis provided evidence that the protein was able to re-direct human FcγR+ effector
cells to kill an anti-MOG+ target cell line in a specific manner. In a syngenic ex vivo situation,
MOG-Fc induced the specific depletion of MOG-reactive B cells from transgenic animals.
Investigation of the most relevant systems in vivo showed that the recombinant protein was
capable of reducing anti-MOG antibody titers in an animal model. This reduction was still
observed at time points when protein levels in the circulation were below detection limit,
suggesting that the long-term reduction in autoreactive antibody titers was due to depletion of
the autoreactive B cell compartment, and not due to short-term adsorption of MOG-Fc
complexed with anti-MOG immunoglobulin. Indeed, the quantification of MOG-reactive B
cells after treatment showed that those B cells were specifically depleted in the treated
animals. This depletion was observed in anti-MOG transgenic TH mice and also in a wild-
type mouse system transferred with syngenic MOG-reactive B cells.
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Fig. 21. Depletion of MOG-reactive B cells by MOG-Fc in wt mice. BL/6 mice were transferred i.v. with
purified B cells from anti-MOG transgenic TH mice. Following transfer on day 0, animals were treated with
PBS (black and white bars), isotype control (human IgG1, white bars) or MOG-Fc (black bars) on days 1, 2
and 3 by i.p. injection. 5 animals were analyzed per group. A. Serum IgM and IgG titers against MOG on day
6 post-transfer, as determined by ELISA. B. FACS analysis of MOG-reactive B cells in peripheral blood.
5.5. Effect of MOG-Fc treatment in EAE
Experimental autoimmune encephalomyelitis is an induced autoimmune disease of the CNS
and the established disease model for multiple sclerosis (MS). Pathology in EAE is mediated
mainly by a Th1 response, and therefore EAE is not a prototype model for antibody-mediated
autoimmunity. However, MOG-specific autoantibody responses are thought to exacerbate
EAE pathology. For this reason, it was investigated whether treatment with the MOG-Fc
fusion protein had an effect on EAE disease progression and severity.
The MOG M36-induced EAE was chosen as a suitable disease model70. Upon immunization
with the M36 peptide, SJL/J mice develop a chronic but relatively mild CNS disease clinically
characterized by episodes of recovery and relapse. It was decided that any therapeutic
intervention had to be started after the first signs of disease in order to closly mimic a
situation that may be encountered in human therapy. Mice were treated after cessation of the
first clinical symptoms (see Fig. 22) with 3 doses of 100 µg each of MOG-Fc every other day,
a dosing regimen that had shown to be effective in the depletion of B cells from transgenic
TH mice.
The MOG-Fc treated animals were spared from clinical symptoms of EAE for a period of 5
days after the untreated control group presented with first signs of disease (Fig. 22). Disease
scores in the non-treated control group averaged a mean of 2 (N=5), while no signs of disease
whatsoever were observed in the treated animals for 23 days post immunization. However, on
day 24 p.i., the MOG-Fc treated animals started to show characteristic symptoms of EAE
disease. Remarkably, the disease progressed very rapidly, resulting in a clinical score >4
within 27 days post immunization. The animals had to be sacrificed at this clinical stage. The
course of this delayed-type, hyperacute pathology was significantly more severe in the treated
animals than in the non-treated control group, which recovered from the second phase of
M36-induced EAE within 26 days post immunization. At that time point, the MOG-Fc treated
animals presented with an average score > 3.5.
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Fig. 22. Effect of MOG-Fc treatment on EAE. SJL/J mice were immunized with M36 peptide on day 0.
On days 17, 19 and 21, animals were treated with 100 µg of MOG-Fc protein in PBS via i.p. injection.
No clinical signs of disease were observed for the MOG-Fc treated group (red) until day 24 post-
immunization, whereas the untreated control group developed EAE by day 21. At day 24, treated animals
presented with first signs of clinical EAE. Rapid disease progression was observed in the treated group.
5.6. Fine specificity of the T-cell response in SJL/J mice
Due to the severe exacerbation of EAE observed after MOG-Fc treatment, it was
hypothesized that treatment must have induced a highly pathogenic, MOG-specific T-helper
response, much like the one seen with animals immunized with bacterially produced,
recombinant MOG in CFA69. Responses versus MOG in the SJL/J mouse system are always
directed against a single epitope contained within the extracellular domain of the MOG
protein, however. Therefore, it was decided to further analyze the specificity of the SJL/J T-
cell response against this epitope, designated M36, with the aim of discovering mutations
within the epitope that would abolish recognition by M36-specific T cells, and thereby
prevent undesired activation of MOG-specific T cells.
5.6.1. Alanine scan of M36 epitope
In the chosen SJL/J mouse model system, immunization with MOG induces a T-cell response
against two main regions: sequence 1-22 and 92-106 (M36) of the MOG extracellular
domain70. While clones against 1-22 are incapable of inducing disease, clones versus M36 are
encephalitogenic and induce EAE upon transfer into recipient animals70. Therefore, the M36
region was analyzed for TCR contact residues via alanine scanning.
A panel of 17 peptides was synthesized. These included human and mouse M36 wild-type
peptide, which differ at position 5 (Y in mouse, F in human). It was of importance to verify
that mouse T cells would also recognize the human peptide, since the MOG-Fc protein
contains the extracellular domain of human MOG. Stimulation of the mouse M36-specific T
cell line with human M36 peptide resulted in similar proliferative responses, as measured by
3H incorporation assay (see Fig. 23B). On the  same note, T-cell proliferation induced by
human M36 was dose-dependent (Fig. 23A), providing further evidence that T-cell
stimulation induced with the human M36 wild-type peptide was peptide-specific. Under the
same experimental conditions, a set of single alanine-substituted peptides was tested for their
potential to induce proliferation of the M36-responsive T cells. Various alterations in
stimulation potential were discovered (see Fig. 23B), ranging from a stimulation index (S.I.)
comparable to wild-type (alanine substitution for G at position 4) down to an almost complete
lack of stimulation, at the level of the medium control (S.I. = 1). The peptides found to induce
the lowest S.I. values (alanine substitutions at positions 5, 8, 10, 12 and 13) were further
tested for their ability to prevent proliferation induced by wild-type M36 peptide.
In a peptide competition experiment, SJL/J antigen-presenting cells (APCs) were pre-pulsed
with human M36 peptide for 2 hours. After a washing step with medium, substituted peptides
were added at equal concentrations, and proliferation was assessed by standard 3H
incorporation assay. It was found that peptides substituted at positions 10, 12 and 13 were
able to completely suppress proliferation induced by the wild-type peptide (Fig. 23C). Taking
into account a recent report that predicted the ligand motif of the MHC class II molecule H2-
AS expressed in the SLJ/J mouse strain71, amino acids 10 (R) and 13 (S) are likely MHC class
II anchor amino acids. In order to generate mutant MOG proteins with reduced T-cell
activation capacity, each mutation was separately introduced into the wild-type MOG-Fc
protein.
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Fig. 23. A. Dose response of M36 T-cell line to M36 peptide. M36-specific mouse T cell line was stimulated
with SJL APCs loaded with human M36 peptide in decreasing concentrations. Proliferation was assessed in a
dose response experiment by standard 3H-thymidine incorporation assay. B. Proliferation of M36 T-cell line
to mutated M36 peptides. Mutated versions of M36 peptide were synthesized. A panel of 15 peptides was
generated, each carrying a single amino acid point mutation to alanine (ala-scanning). Proliferation of M36-
responsive T-cell line to peptide stimulation was assessed by 3H-thymidine incorporation assay. Stimulation
index was calculated as S.I. = (cpm) / (cpm medium control). C. T-cell antagonist assay using mutated M36
peptides. Peptides identified as non-stimulatory for M36 T cells were further tested for their ability to
compete with wt M36 peptide. Irradiated SJL splenocytes were used as APCs and loaded with wt M36
peptide. After 2 h of incubation, APCs were washed with medium, and alanine-substituted peptide variants
were added as well as M36 T cells. Peptides substituted at positions 10, 12 or 13 of the M36 region were able
to inhibit proliferation of M36 T cells to wt peptide.
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5.7. Generation of mutated MOG-Fc proteins (R-MOG, S-MOG)
Mutated MOG-Fc proteins carrying a single amino acid substitution to alanine at position 10
(R replaced by A, designated R-MOG) and 13 (S replaced by A, designated S-MOG) of the
MOG extracellular domain were generated. Constructs encoding the desired nucleotide
exchanges were generated by site-directed mutagenesis. The encoded proteins were generated
and purified exactly as previously described for the wild-type MOG-Fc protein. As shown in
Fig. 24 for the S-MOG protein, binding of the mutated extracellular domain of MOG to
MOG-specific TH B cells in isolated splenocytes was still intact. Panel A shows selective
binding to transgenic (lower panel) but not to wild-type splenocytes (upper panel). No binding
to CD5-positive T cells was evident (panel B). In panel C, binding to B220+ anti-MOG
transgenic TH B cells is shown in the absence of binding to wt B cells. Panel D shows the
secondary antibody control stainings without prior incubation with Fc fusion protein.
Therefore, mutated proteins were generated that retained specific binding activity to their
target B cells.
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Fig. 24. Binding of S-MOG protein to splenocytes from TH mice vs. negative wt controls. Flow
cytometric analysis of cell binding properties. Binding of Fc fusion protein to B cells of Ig-MOG
transgenic TH mice. Splenocytes from wt (upper panel) and TH mice (lower panel) were prepared and
incubated with mutated MOG-Fc protein. MOG-Fc bound to IgM-positive cells was detected by FITC-
labeled human Fcγ-specific antibody (huFc). Stainings show selective binding to transgenic B cells (panel
A, C) in the absence of unselective binding to T cells, as detected through the marker CD5 (panel B). No
staining was detected with the secondary anti-Fc antibody alone in the absence of MOG fusion protein
(D).
5.8. Treatment of PLPs-immunized animals transferred with TH B cells
The central question that had to be answered regarding the mutated MOG-Fc proteins is
whether they induce a MOG-specific T-cell response. Since the SJL/J M36-specific T-cell
line used for the investigation of peptide-induced proliferation was insensitive to MOG
protein-induced stimulation, it was decided to employ the most relevant in vivo model for
obtaining therapeutic efficacy, e.g., clinical disease score. An EAE model was chosen that did
not rely on immunization with the MOG antigen, but one that rested on immunization with
PLPs peptide and transfer of MOG-specific TH B cells as an exacerbating factor. The TH
transfer model had shown to be responsive to MOG-Fc induced depletion of B cells (compare
section 5.4.2.4.) and permitted the investigation of immunopathology induced by treatment.
This was achieved in the absence of pre-sensitization to MOG, due to the MOG-independent
immunization regimen used to induce EAE.
The disease progression in the PLPs transfer model can be seen in Figure 25. Animals were
treated via i.p. injection on days 7, 8 and 9 after PLPs immunization with 3 times 100 µg of
protein for each treatment cycle. While the untreated control group showed an average score
of 1 by day 15, the group treated with wild-type MOG-Fc protein presented with a rapidly
progressive, monophasic disease course that culminated in a score > 4 by day 24 post
immunization. Animals treated with both R-MOG or S-MOG variants showed no significant
difference in clinical score compared to the wild-type MOG-Fc treated group. Very clearly,
all 3 treatment regimens induced an exacerbated EAE progression that resulted in a disease
that was significantly more severe than in the untreated control animals. Thus, no clinical
benefit could be observed by treating EAE with MOG-Fc, or one of the mutated MOG-Fc
variants, designed to minimize T-cell stimulation induced by the MOG domain of the protein.
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Fig. 25. Modified MOG-Fc proteins exacerbate EAE. Animals were immunized on day 0 with PLPs and
transferred with TH B cells on day 1. On days 7, 8 and 9, mice were treated with 100µg of recombinant protein
via i.p. injection. Untreated control animals present with mild clinical symptoms of EAE, not exceeding a
maximum score of 2. All animals treated with MOG-Fc (red), S-MOG (blue), or R-MOG (green) develop
hyperacute EAE by day 17 post immunization.
6. Discussion
6.1. In vitro properties of MOGxCD3 fusion protein
Bispecific antibodies have been investigated since the mid-1980s72-74. In these early reports, it
was shown that bispecific antibodies (bsAbs) could override the natural specificity of an
effector cell for its target and 're-direct' the effector to kill a target cell that it would otherwise
ignore. In order to mediate re-directed lysis, a bsAb must bind directly to a triggering
molecule on the effector cell74;75 while simultaneously cross-linking target and effector cells
for specific killing. By varying the specificities of the anti-effector and anti-target domains of
the bsAb, a range of effector functions can be recruited against a variety of target cells. In
fact, the early 1990s saw the first clinical investigations evaluating bsAbs as therapeutic
agents, mainly in cancer therapy76;76-83. However, a major obstacle in using bispecific
antibodies harnessing the potential of T cells irrespective of their MHC restriction, was
encountered in the strict requirement of T-cell responses for costimulatory or regulatory
molecules84. As a consequence, investigators have used approaches for the simultaneous
engagement of co-stimulatory molecules, such as CD28, while at the same time cross-linking
an activating receptor with the same molecule85, or T cell mitogens such as IL-2 were chosen
as co-medication84. For instance, bispecific antibodies triggering CD3 have been applied in
combination with anti-CD28 Abs86-88. Characteristic outcomes of these trials included serious
side effect profiles and low efficacy of bsAb treatment84. In order to overcome these
limitations, it was chosen to incorporate the anti-CD3 moiety as described by Löffler et al49.
In contrast to a diabody format, which possesses a rather rigid structure, the use of flexible
serine-glycine linkers provides for a bispecific scFv-format that reduces the distance from
target cell to effector to a minimum89. This format has proven to be highly potent in recruiting
T-cells for re-directed lysis of target cells in the absence of simultaneous engagement of
accessory molecules on T cells by additional agents (Dreier et al., submitted)49;90.
In  order to extend the concept of bispecific antibodies to the targeting of autoreactive B cells,
a protein was designed that incorporated the extracellular domain of the auto-antigen MOG at
the N-terminus fused to the heavy chain Fv fragment of a C-terminally attached anti-CD3
scFv49 directed against human CD3ε. The MOGxCD3 protein was expressed in CHO cells
and purified using a His-6 tag at the C-terminus. Expression in CHO cells has proven to be
superior for the generation of correctly folded, active bispecific scFv antibodies.
ELISA and Western blot analysis (see Figures 8 and 9) revealed that the MOGxCD3 fusion
protein was produced as an intact molecule of the predicted size. Using the conformation-
dependent anti-MOG monoclonal antibody 8.18-C552 for capture in ELISA, it was shown that
the extracellular domain of human MOG was indeed correctly folded. FACS analysis of
purified human T cells incubated with the fusion protein (Fig. 11) showed that incorporation
of a non-immunoglobulin domain into the scFv format at the N-terminus did not abrogate its
binding to human CD3 on T cells. Other groups have used single chain fusion proteins for the
targeting of tumor cells over-expressing growth factor receptors via anti-CD3 or anti-CD64
scFv Abs91;92. Effector targeting domains were generally attached at the N-terminus, which
can be a limitation with regard to the ligand, which then needs to be fused in a C-terminal
position. Thus, the MOGxCD3 molecule provides for a versatile immunoligand platform due
to its incorporation of a functional anti-CD3 domain at the C-terminus.
Employing a FACS-based cytotoxicity assay54;55 using a hybridoma cell line selected for
expression of cell-surface bound anti-MOG antibody, it could be shown that MOGxCD3
mediated re-directed lysis of MOG-reactive hybridoma cells (Fig. 15, Fig. 16). Complete
elimination of target cells was observed with freshly isolated human CD3-positive cells
without prior stimulation with T-cell mitogens, such as IL-2.
A dose-response analysis showed that an optimal concentration of MOGxCD3 fusion protein
was reached at 10 µg/ml, leading to elimination of  >80% of target cells (Fig. 15A). Lysis was
dependent on the presence of effector cells (Fig. 15B, 2nd bar) and on the effector-to-target
cell ratio (Fig. 16), as well as on the presence of the MOGxCD3 protein (Fig. 15B, 3rd bar).
Taken together, the data obtained for the MOGxCD3 bispecific molecule show that
unstimulated human T cells can be re-directed to induce the specific lysis of hybridoma cells
carrying autoreactive cell-surface immunoglobulin. In vivo studies of the bispecific T-cell
recruiting MOGxCD3 molecule in rodents or primates could not be performed due to the
specificity of the scFv targeting domain for human CD3ε. For the investigation of targeting
autoreactive B cells in a physiological situation, a fusion protein composed of an Fc effector
domain and the MOG targeting moiety, designated MOG-Fc, was generated and studied in the
MOG-Ig transgenic TH mouse system.
6.2. Rationale for construction of Fc fusion protein
Therapeutic options for the treatment of antibody-mediated autoimmune diseases are very
limited and dissatisfactory. Treatment regimens include immunosuppressive drugs,
corticosteroids or plasmapheresis, which generally act only in a transient fashion, or may lead
to a general immunodeficiency. In search for a more specific approach, it was attempted to
selectively deplete autoantibody-producing B cells through targeted lysis by immune effector
cells, employing the bispecific fusion protein MOG-Fc. The intention was to combine human
MOG for the specific targeting of MOG-reactive B cells with an immune effector mechanism
leading to an efficient and at the same time well-tolerated elimination of target cells. Other
approaches were disregarded, such as bacterial toxin fusions, because of their relatively small
therapeutic window and high immunogenicity93;94. Because of its high tolerability, the Fc part
of human IgG1 was employed instead. This immunoglobulin (Ig) isotype is well-suited for
induction of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent
cytotoxicity (CDC) and is validated for the efficient elimination of tumor cells by the
marketed antibody therapeutics trastuzumab48 and rituximab40. Another potential advantage is
the dimerization of the CH2 and CH3 domains in the human IgG heavy chain that increases
the avidity of target cell binding by linking two MOG molecules. In addition, human Fcγ1 can
efficiently bind murine Fcγ receptors (see Fig. 17B)64 thus facilitating functional studies with
the MOG-Fc protein in transgenic mice expressing anti-MOG Abs95.
The choice of the most suitable Fc effector domain was a consideration of central importance.
A number of previous studies have shed light on the interaction of Ig isotypes and Fc
receptors42;96-98. It has become clear that IgG Fc contains distinct Fc receptor (FcR) binding
sites96;99. These are different from the ones recognized by neonatal FcR100;101 or
staphylococcus protein A. In fact, whereas the CH2-CH3 interface of the IgG Fc domain
contains the binding site for the neonatal Fc receptor (FcRn), protein A and the low-affinity
FcγRIII102 (CD16), the binding sites for the FcγRII family and FcγRI differ. Being expressed
on neutrophils and macrophages, Fcγ receptors of type IIa (CD32) and FcγRI (CD64) possess
important functions in cellular immunity, however2. Therefore, fusion proteins aimed at
harnessing the potential of cells positive for either FcγR must encompass the critical binding
residues (Fig. 23). For this reason, the lower hinge and adjacent CH2 domain were
incorporated into the MOG-Fc fusion protein. These domains were found to be critical for
interaction between FcγRIIa, FcγRI and human IgG by mutational studies96;103.
As glycosylation of the CH2 domain is thought to be required for efficient binding to Fc
receptors96 as well as for 'recycling' of IgG through the neonatal Fc receptor64;97;98, the choice
of an appropriate eucaryotic expression system is also an important consideration. Therefore,
the dhfr-deficient chinese hamster ovary (CHO) cell line49 was chosen as an eucaryotic
system for expression of the recombinant MOG-Fc protein.
6.3. Investigation of targeting autoreactive B cells with Fc fusion protein
The MOG-Fc protein was expressed and purified as a disulfide-linked dimer in CHO-cells
and was shown to bind to both MOG-reactive B lymphocytes, B cell hybridoma cells and to
FcγR+ phagocytes. MOG-Fc treatment resulted in effective and specific effector cell-
dependent lysis of MOG-specific hybridoma cells. To explore the cytotoxic potential of
MOG-Fc on regular B cells in vivo, the fusion protein was studied in transgenic knock-in
mice (TH mice). These mice possess large numbers of MOG-specific B cells, and
correspondingly high titers of anti-MOG Abs, due to the site-directed targeting of a MOG
specific Ig VH gene (Fig. 1)95. A marked decrease in anti-MOG IgG titers was observed
throughout the observation period (Fig. 18D), even though human Fc proved to be
immunogenic in the animals (Fig. 18C). This result shows that the effect of MOG-Fc on B
cells, e.g. autoantibody titers, outweighed a potential induction of anti-MOG antibodies in the
course of treatment. As shown in Fig. 18A and 18B, wild-type mice do develop an antibody
titer to both the human Fc part as well as the MOG domain of the fusion protein 22 days after
being treated, which is not surprising considering the immunological unique expression
profile of MOG69.
Having observed that MOG-Fc lowered autoantibody titers in vivo, it was investigated
whether the fusion protein exhibited cytotoxic activity against the autoreactive B-cell
population in anti-MOG transgenic mice. In fact, MOG-Fc had the ability to deplete primary
anti-MOG-positive B cells from TH mice ex vivo and in vivo. Elimination of MOG-reactive B
cells ex vivo was efficient (on the order of 70% within 16 hours, Fig. 19), while in vivo it was
lower but still significant among the population of highly MOG-reactive B cells in TH mice
(Fig. 20). This result can be explained as follows:
 First, it should be noted that TH mice have an extremely high titer of circulating MOG-
reactive antibodies95, which interferes with the binding of MOG-Fc to MOG-specific B cells.
Second, the large pool of continuously replenished, MOG-specific B lymphocytes in TH mice
represents an exaggerated large target cell population which may partly resist specific drug
depletion in vivo. In contrast, the frequency of autoreactive B cells in human autoimmune
disease is much lower8;104.
To study the effect of MOG-Fc on a limited number of autoreactive B cells among a high
background of normal B cells from the endogenous B-cell pool, a wild-type transfer model
was established. The model consisted of purified B cells obtained from TH mice that were
transferred into syngenic wild-type recipient animals by intravenous injection. In this TH
transfer model, the treatment of transferred mice with MOG-Fc resulted in efficient depletion
of about 70% of all MOG-reactive B cells, as detectable 6 days after B-cell transfer and 2
days after the last treatment (Fig. 21A). Four to six days after transfer, most TH-derived B
cells detected were actively switching, IgM− MOG+ IgG+ B-cell blasts. In MOG-Fc-treated
mice, but not in control mice, serum titers of MOG-binding Abs were reduced, despite the
presence of actively secreting plasma cells, which cannot be targeted via ADCC by MOG-Fc.
Thus, the action of MOG-Fc on autoreactive B-cells is not restricted to resting B cells (Fig.
19, 20) but includes also the active elimination of activated B-cells and the reduction of
circulating Abs (see Fig. 21).
The ability of MOG-Fc to bind and eliminate autoreactive B cells even in the presence of high
anti-MOG antibody titers in vivo demonstrate its utility for a novel therapy of antibody-
mediated autoimmune diseases. While bone marrow-resident plasma cells, which carry little if
any Ig on their surface, cannot be eliminated by the described approach, the introduction of
recombinant antigen into circulation by the fusion protein could prove to be of additional
therapeutic benefit. MOG-Fc could bind pathogenic autoantibodies and route them to
clearance. Theoretically, the formation of such immune complexes might recall pathogenic
pathways, such as glomerulonephritis. However, signs of clinical immune complex disease in
TH mice monitored for more than two months following treatment with MOG-Fc were not
encountered. Anaphylactic reactions were not seen either. Sustained elimination of MOG-
reactive, resting, activated and possibly also memory B cells may, in the long run, lead to a
depletion of MOG-secreting plasma cells as well. This is underscored by the long-term
reduction in anti-MOG IgG in TH mice treated with MOG-Fc (see Fig. 18D).
It has to be noted that MOG is a strictly CNS-specific auto-antigen that is neither expressed in
the thymus nor in the periphery, which sets it apart from other CNS constituents like myelin
basic protein (MBP)9 or other target antigens of B-cell mediated autoimmune attack in
indications like pemphigus vulgaris and myasthenia gravis3;105. Thus, MOG-specific clones
are not subject to clonal deletion or peripheral tolerance induction, making MOG a potent
encephalitogen11. It should be emphasized that MOG was chosen mainly as a suitable model
antigen for the study of B-cell depletion in the absence of an inflammatory context, as would
be encountered in EAE or MS. In the case of Th2-dominated and truly B-cell mediated
autoimmune indications, the respective antigen is usually expressed in thymus and periphery,
and thus participates in the generation of tolerance. In summary, the present data demonstrate
the potential of MOG-Fc-based compounds in the attenuation of autoreactive B-cell responses
in vivo.
6.4. Effect of MOG-Fc treatment in EAE
MOG is an important auto-antigen involved in the pathogenesis of multiple sclerosis, and
MOG-induced EAE is the only model of MS to evoke both encephalitogenic T cells as well as
demyelinating autoantibodies69. Due to the highly encephalitogenic potential of MOG when it
is used in a CFA emulsion to immunize experimental animals for the induction of EAE, it was
clear from the beginning that one might encounter limitations when using this format as a
therapeutic modality in EAE. In addition, EAE is a classical Th1-mediated autoimmune
disease where autoantibodies may have an exacerbating function, but B cells are not required
for disease development. In fact, EAE can even be induced in B-cell deficient mice106;107. On
the other hand, tolerization regimens with high-dose antigen therapy of MOG-induced EAE
have been described for the marmoset primate model108. In this model, the induction of MOG-
EAE could be prevented by giving repeated high doses of the soluble antigen. In the long run,
the treatment failed, due to the appearance of a pathogenic, MOG-specific humoral response
after cessation of treatment. However, this report showed that MOG-EAE can be positively
modulated by high doses of the antigen itself, which led to the decision to investigate the
effect of MOG-Fc treatment in EAE.
The M36-induced EAE model was chosen as a first in vivo system to investigate therapeutic
efficacy (see Fig. 22). Surprisingly, treated animals showed no clinical signs of disease for a
period of 4 to 5 days after the non-treated group had developed the first clinical features of
EAE. Thereafter, however, disease progression was rapid and clearly more severe than in the
untreated control group. Due to the rapid onset and hyperacute profile of disease, reminiscent
of rMOG-induced EAE, it was hypothesized that the treatment had induced a MOG-specific
T-helper response. However, alterations of the immunodominant, encephalitogenic MHC
class II epitope within the MOG-Fc protein (Fig. 23), introduced in order to prevent T-cell
stimulation by the MOG fusion protein, did not result in a measurable change in clinical
outcome after treatment, as investigated in the PLPs-induced EAE transfer model (see Fig.
25). There may be a number of reasons for the failure of the modified proteins to positively
modulate the course of EAE. First, the immunodominant epitope within the MOG
extracellular domain was characterized using a monoclonal T-cell line selected for
responsiveness to M36 stimulation. Clearly, the MOG-specific T-cell response in vivo is
oligoclonal, even though sequencing of TCR variable genes has shown that just a few T cell
clones dominate the response (A. Iglesias, personal communication). The M36 T-cell line
may have been too much of an artificial system, not representative of the in vivo situation.
Secondly, the appearance of subdominant MOG-specific clones even after a possible
elimination of the dominant T-cell response is possible, and these clones may be of equally
pathogenic potential. Thirdly, it has to be remembered that MOG-Fc is a fully human protein.
Therefore, the Fc part is immunogenic in mice, as proven by the detection of mouse antibody
titers against human Fc in the treated animals. Thus, a B cell that has bound MOG-Fc via the
protein's MOG part will still be able to present immunogenic epitopes contained within the Fc
portion, and will receive help from Fc-specific T helper cells. This could lead to the long-term
induction of a MOG-specific Ig response, even in the absence of encephalitogenic, MOG-
specific MHC class II epitopes contained within the MOG domain of the protein. Clearly,
using MOG-Fc to positively modulate immunopathology in EAE or even MS is not feasible.
The MOG system should be regarded as purely a model system suitable for the investigation
of B-cell targeting strategies, which may then be transferred to other, possibly less potent
target auto-antigens involved in truly B-cell mediated autoimmunity.
6.5. Perspectives
In the work presented here, novel recombinant proteins aimed at specifically targeting
autoreactive B cells were generated. These bispecific antibody fusion proteins were shown to
induce re-directed lysis of autoreactive B cells, thus reducing the number of potentially
pathogenic B cells and corresponding autoantibody titers in vivo. These findings constitute
core requirements for the specific immunotherapy of antibody-mediated autoimmune
diseases.
On the basis of data obtained from MOG-Fc in the MOG-Ig model system, informed choices
can be made in order to engineer refined recombinant proteins for application in B-cell
mediated autoimmunity. These proteins should fulfill several requirements:
1. Maximum induction of re-directed lysis through engagement of effector cells.
2. Minimal binding to antigen-presenting cells.
3. Long serum half-life with low side effect profile.
4. Low immunogenicity of the auto-antigen domain.
For the general format used for engagement of FcγR+ effector cells, further adjustments to the
Fc effector domain can be considered in addition to those already outlined and incorporated in
Fig. 26. Binding sites of human IgG1 for FcR. A. IgG1 residues comprising the binding site for FcRI and
FcRII. The two Fc heavy chains are in light and medium gray; carbohydrate is in dark gray. Residues that
affected binding to all FcR are in red; the FcRI binding site is composed only of red residues. Residues that
showed improved binding to FcRII and FcRIIIA are in magenta. Residues that showed reduced binding
only to FcRII are in yellow. Residues that showed  50% improved binding only to FcRII are in green. B.
IgG1 residues comprising the binding site for FcRI and FcRIIIA. The two Fc heavy chains are in light and
medium gray; carbohydrate is in dark gray. Residues that affected binding to all FcR are in red; the FcRI
binding site is composed only of red residues. Residues that showed improved binding to FcRII and
FcRIIIA are in magenta. Residues that showed reduced binding only to FcRIIIA are in yellow. Residues
that showed  25% improved binding only to FcRIIIA are in green. Glu430, involved in a salt-bridge with
Lys338, is shown in blue.  From Shields 2001.
the general considerations in section 6.2. In tables II and III, the binding of mutated human
IgG1 Fc regions to Fc receptors is characterized99. It would be tempting to investigate the
potential of mutated Fc fusion proteins designed to maximize the engagement of FcγRIIIA
while reducing the binding to the FcγRII family. Accordingly, the hope would be that proteins
engineered in this way would lead to increased triggering of NK cells through the low-affinity
FcγRIIIA while reducing the binding to APCs carrying FcγRII in the absence of CD16. Thus,
presentation of auto-antigen should be reduced, leading to reduced immunogenicity. Also,
serum half-life may be prolonged in the absence of high-affinity binding to FcγRI.
Notably, the mutation of S298 to alanine is characterized by an increase in CD16 binding,
even in combination with other mutations in its vicinity (table III).  K334A exhibited a
significant increase in ADCC when incorporated into anti-HER2 IgG1 variants. This increase
was additive when K334A was present with S298A, and was even further enhanced when
E333A was present99. Thus, modifications of the Fc region may lead to a bispecific protein
with optimized effector function.
In spite of the importance of the general protein format, attention must be given to the
investigated target indication and the corresponding auto-antigen. Promising antigens
involved in B-cell mediated autoimmunity could be the desmogleins 3 and 1, well-defined
targets for pathogenic antibodies in pemphigus vulgaris109, or the extracellular part of the
alpha chain of the acetylcholine receptor, the main auto-antibody target structure in
myasthenia gravis110.
For pemphigus vulgaris, fusion proteins could be envisioned that accompany two B-cell target
specificities into a single Fc molecule. This could be accomplished by using a
heterodimerization domain in the IgG1 heavy chain, engineered for directed dimerization
through additional disulfide bonds in combination with "knobs-into-holes" mutations111. This
modified IgG1 Fc backbone could be used for expression of the Dsg-1 and Dsg-3
extracellular domain, each fused to a separate heavy chain, resulting in a molecule with both
specificities. A fusion protein of this kind may lead to depletion of both Dsg-1 as well as Dsg-
3 specific B cells.
Myasthenia Gravis (MG) constitutes another example of a truly B-cell mediated autoimmune
disease. MG is a T-cell dependent, antibody-mediated autoimmune disease of the
neuromuscular junction, in which the nicotinic acetylcholine receptor (AchR) is the major
autoantigen. Autoantibodies to the alpha-chain of the nicotinic acetylcholine receptor present
at the neuromuscular junction block neuromuscular transmission. MG is a fatal affliction;
patients affected with this disease develop progressive weakness potentially leading to death.
Experimental autoimmune MG (EAMG), inducible in various animal species by
immunization with AchR or by passive transfer of anti-AchR antibodies, is a reliable model of
the human disease, suitable for the investigation of therapeutic strategies112-114. MG is
currently treated mainly by acetylcholinesterase inhibitors and by generalized
immunosuppression. These treatments have been effective for both MG and EAMG but are
often associated with severe side effects. Ideally, the treatment should be specific and should
suppress selectively the immunological reactivity that leads to the neuromuscular disorder
without impairing the entire immune system. The immune response to AchR is highly
heterogeneous115-118 and a wide variety of T- and B-cell epitopes have been defined in MG
and EAMG. Thus, the search for new molecules suitable for treatment of MG should deal
with this heterogeneity. Candidate molecules for antigen-specific immunotherapy of MG
should share specificities with the native antigen without being pathogenic and should be
available in sufficient amounts.
The extracellular portion of the AchR alpha-subunit is the target for the majority of the anti-
AchR antibodies in MG sera119. Recombinant proteins corresponding to this region
encompass T and B cell epitopes and can be prepared in large amounts. They therefore
represent a potential substitute for the entire antigen for immunotherapy studies. These
recombinant fragments were able to attenuate EAMG passively transferred by pathogenic
monoclonal anti-AchR antibodies120;121. While passive adsorption of pathogenic antibodies by
recombinant autoantigen fragments has already proven successful in treatment regimens of
EAMG122;123, the autoreactive B cell as origin of these pathogenic antibodies is not addressed.
Therefore, the extracellular domain from amino acids 1-210 of the human AchR alpha chain
could be combined with an effector domain for the recruitment of immune effector cells, thus
leading to depletion of autoreactive B cells and attenuation of disease.
The work presented here describes novel recombinant proteins with the proven ability to
deplete autoreactive B cells as the root cause of pathogenic autoantibodies. The concept of
targeting B cells specific for autoantigens for elimination through immune-effector
mechanisms is a novel and provocative one. Applying the platform format generated using the
MOG model system to B-cell mediated autoimmune disease models will show whether the
antigen-specific modulation of the B cell response in humoral autoimmunity results in a
clinical benefit. This could lead to antigen-specific therapy of B-cell mediated autoimmune
diseases, an ultimate goal of applied immunology.
Table II
Binding of human IgG1 non-Ala variants to human FcRII and FcRIIIA
--------------------------------------------------------------------------------
Varianta                   FcRIIAb mean (S.D.)        FcRIIB mean (S.D.)          FcRIIIA mean (S.D.) nc
--------------------------------------------------------------------------------
D265N 0.02 (0.01) 0.03 (0.01) 0.02 (0.01) 3
D265E 0.11 (0.04) 0.03 (0.01) 0.02 (0.01) 3
S267G 1.18 (0.10) 0.95 (0.14) 0.08 (0.02) 4
S267T 0.42 (0.10) 0.45 (0.01) 0.05 (0.05) 3
D270N 0.03 (0.02) 0.05 (0.05) 0.04 (0.03) 5
D270E 0.08 (0.01) 0.06 (0.01) 0.90 (0.17) 3
D280N 1.07 (0.18) 1.22 (0.19) 1.16 (0.21) 6
E293D 0.90 (0.02) 0.88 (0.07) 0.37 (0.07) 3
S298T 0.29 (0.19) 0.27 (0.19) 0.73 (0.21) 6
S298N 0.05 (0.03) 0.08 (0.08) 0.06 (0.03) 5
R301M 1.29 (0.17) 1.56 (0.12) 0.48 (0.21) 4
P331S 0.91 (0.08) 0.78 (0.07) 0.58 (0.19) 4
E333Q 0.70 (0.05) 0.64 (0.09) 1.05 (0.09) 3
E333N 0.59 (0.04) 0.52 (0.07) 0.56 (0.10) 4
E333D   1.26 (0.04) 3
K334R 1.15 (0.09) 1.33 (0.18) 0.68 (0.07) 5
K334Q 1.08 (0.11) 1.10 (0.21) 1.23 (0.08) 7
K334N 1.16 (0.11) 1.29 (0.30) 1.11 (0.12) 8
K334E 0.74 (0.15) 0.72 (0.12) 1.30 (0.09) 6
K334V 1.13 (0.11) 1.09 (0.15) 1.34 (0.18) 3
K338M 0.99 (0.13) 0.93 (0.15) 0.49 (0.04) 2
--------------------------------------------------------------------------------
a  Residue numbers are according to the Eu numbering system.
b  Values are the ratio of binding of the variant to that of native IgG1 at 0.33 or 1 µg/ml. A value greater
than 1 denotes binding of the variant was improved compared with native IgG1, whereas a ratio less
than 1 denotes reduced binding compared to native IgG1.
c  Number of independent assays for FcRIIA, FcRIIB, and FcRIIIA. At least two separately expressed
and purified lots of each variant were assayed.
Table adapted from Shields 2001.
Table III
Binding of human IgG1 combination variants to human FcRn and FcR
--------------------------------------------------------------------------------
Varianta       FcRnb mean (S.D.) n               FcRIIAc                          FcRIIB                         FcRIIIA
--------------------------------------------------------------------------------
S267A  1.41 (0.00) 2 1.56 (0.16) 2  0.96 (0.12) 2
H268A
S267A  1.62 (0.15) 2 2.01 (0.45) 2 1.04 (0.12) 2
E258A
S267A  1.60 (0.18) 3 1.72 (0.13) 3 0.88 (0.07) 3
R255A
S267A  1.51 (0.13) 3 1.82 (0.32) 3 0.95 (0.05) 3
E272A
T256A  0.44 (0.03) 2 0.22 (0.04) 2 1.41 (0.06) 2
S298A
S298A  0.34 (0.05) 5 0.16 (0.08) 5 1.53 (0.24) 5
E333A
S298A  0.41 (0.07) 6 0.19 (0.08) 6 1.62 (0.34) 6
K334A
S298A  0.34 (0.15) 10 0.15 (0.06) 10 1.51 (0.31) 10
E333A
K334A
E380A 8.0 (1.0) 6 1.02 (0.07) 2 1.05 (0.11) 2 1.02       1
N434A
T307A 11.8 (1.5) 5 0.99 (0.06) 2 0.99 (0.11) 2 0.96       1
E380A
N434A
L309A 0.9 (0.1) 4 0.98       1 1.04       1 0.92       1
E380A
K288A  2.9 (0.4) 4 0.94 (0.11) 2 0.96 (0.17) 2 0.88       1
N434A
--------------------------------------------------------------------------------
a  Residue numbers are according to the Eu numbering system.
b  Values are the ratio of binding of the variant to that of native IgG1 at pH 6.0.
c  Values are the ratio of binding of the variant to that of native IgG1 at 0.33 or 1 µg/ml. A value greater
than 1 denotes binding of the variant was improved compared with native IgG1, whereas a ratio less
than 1 denotes reduced binding compared with native IgG1.
Table adapted from Shields 2001.
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9. Abbreviations
8.18-C5 anti-MOG monoclonal antibody
ag antigen
APC antigen-presenting cell
bp base pair
BSA bovine serum albumine
cDNA complementary DNA
CFA complete Freund's adjuvant
CH50 total hemolytic complement activity
CHO cells chinese hamster ovary cells
CNS central nervous system
DMEM Dulbecco's modified eagle's medium
E. coli Escherichia coli
EAE experimental autoimmune encephalomyelitis
ELISA enzyme-linked immunosorbant assay
FACS fluorescence activated cell sorter
Fc immunoglobulin Fragment crystallizable
FcR Fc receptor
FCS fetal calf serum
FITC fluorescein isothiocyanate
Ig immunoglobulin
kb kilobase pairs
kDa kilo Dalton
KO knock out
MBP myelin basic protein
MEM-α modified eagle's medium alpha
MHC major histocompatibility complex
MOG myelin oligodendrocyte glycoprotein
MOG-Ig anti-MOG immunoglobulin
mRNA messenger RNA
PCR polymerase chain reaction
PLP proteolipid protein
rpm revolutions per minute
RT room temperature
scFv single chain Fv fragment
SDS sodium dodecylsulfate
TCR T-cell receptor
tg transgenic
Th T-helper lymphocyte
Th1 T helper cell of type 1
Th2 T helper cell of type 2
Tween 20 polyoxyethylene sorbitane monolaurate
wt wild type
10. Reference List
1. Hohlfeld, R. 1997. Biotechnological agents for the immunotherapy of multiple
sclerosis. Principles, problems and perspectives. Brain. 120:865-916.
2. Janeway, C. A. and Travers, P. Immunobiology. The Immune System in Health and
Disease. 2nd edition. 1996.  Current Biology Ltd.
Ref Type: Serial (Book,Monograph)
3. Padberg, F., M. Matsuda, R. Fenk, N. Patenge, B. Kubuschok, R. Hohlfeld, H.
Wekerle, and S. Spuler. 1999. Myasthenia gravis: selective enrichment of
antiacetylcholine receptor antibody production in untransformed human B cell
cultures. Eur.J.Immunol. 29:3538-3548.
4. Link, H., O. Olsson, J. Sun, W. Z. Wang, G. Andersson, H. P. Ekre, T. Brenner, O.
Abramsky, and T. Olsson. 1991. Acetylcholine receptor-reactive T and B cells in
myasthenia gravis and controls. J.Clin.Invest. 87:2191-2195.
5. Amagai, M. 1999. Autoimmunity against desmosomal cadherins in pemphigus.
J.Dermatol.Sci. 20:92-102.
6. Nguyen, V. T., A. Ndoye, and S. A. Grando. 2000. Pemphigus vulgaris antibody
identifies pemphaxin. A novel keratinocyte annexin-like molecule binding
acetylcholine. J.Biol.Chem. 275:29466-29476.
7. Tournadre, A., M. D'Incan, J. J. Dubost, F. Franck, P. Dechelotte, P. Souteyrand, and
M. Soubrier. 2001. Cutaneous lymphoma associated with Epstein-Barr virus infection
in 2 patients treated with methotrexate. Mayo.Clin.Proc. 76:845-848.
8. Nishifuji, K., M. Amagai, M. Kuwana, T. Iwasaki, and T. Nishikawa. 2000. Detection
of antigen-specific B cells in patients with pemphigus vulgaris by enzyme-linked
immunospot assay: requirement of T cell collaboration for autoantibody production.
J.Invest.Dermatol. 114:88-94.
9. Iglesias, A. 2001. Maintenance and loss of self-tolerance in B cells.
Springer.Semin.Immunopathol. 23:351-366.
10. Battegay, M., P. Fiedler, U. Kalinke, F. Brombacher, R. M. Zinkernagel, H. H. Peter,
G. Kohler, and H. Eibel. 1996. Non-tolerant B cells cause autoimmunity in anti-CD8
IgG2a-transgenic mice. Eur.J.Immunol. 26:250-258.
11. Litzenburger, T., R. Fassler, J. Bauer, H. Lassmann, C. Linington, H. Wekerle, and A.
Iglesias. 1998. B lymphocytes producing demyelinating autoantibodies: development
and function in gene-targeted transgenic mice. J.Exp.Med. 188:169-180.
12. Boccaccio, G. L. and L. Steinman. 1996. Multiple sclerosis: from a myelin point of
view. J.Neurosci.Res. 45:647-654.
13. Steinman, L. 1996. Multiple sclerosis: a coordinated immunological attack against
myelin in the central nervous system. Cell. 85:299-302.
14. Ebers, G. C., A. D. Sadovnick, and N. J. Risch. 1995. A genetic basis for familial
aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature.
377:150-151.
15. Sadovnick, A. D. and G. C. Ebers. 1995. Genetics of multiple sclerosis. Neurol.Clin.
13:99-118.
16. Oksenberg, J. R., A. B. Begovich, H. A. Erlich, and L. Steinman. 1993. Genetic
factors in multiple sclerosis. JAMA. 270:2362-2369.
17. Olsson, T. 1992. Immunology of multiple sclerosis. Curr.Opin.Neurol.Neurosurg.
5:195-202.
18. Ben Nun, A., H. Wekerle, and I. R. Cohen. 1981. The rapid isolation of clonable
antigen-specific T lymphocyte lines capable of mediating autoimmune
encephalomyelitis. Eur.J.Immunol. 11:195-199.
19. Lassmann, H., F. Zimprich, K. Rossler, and K. Vass. 1991. Inflammation in the
nervous system. Basic mechanisms and immunological concepts. Rev.Neurol.(Paris.)
147:763-781.
20. Lassmann, H. 1991. Inflammation and the blood-brain barrier. Brain.Pathol. 1:88.
21. Raine, C. S. 1991. Multiple sclerosis: a pivotal role for the T cell in lesion
development. Neuropathol.Appl.Neurobiol. 17:265-274.
22. Martin, R., H. F. McFarland, and D. E. McFarlin. 1992. Immunological aspects of
demyelinating diseases. Annu.Rev.Immunol. 10:153-87.:153-187.
23. Genain, C. P., B. Cannella, S. L. Hauser, and C. S. Raine. 1999. Identification of
autoantibodies associated with myelin damage in multiple sclerosis. Nat.Med. 5:170-
175.
24. Genain, C. P., M. H. Nguyen, N. L. Letvin, R. Pearl, R. L. Davis, M. Adelman, M. B.
Lees, C. Linington, and S. L. Hauser. 1995. Antibody facilitation of multiple sclerosis-
like lesions in a nonhuman primate. J.Clin.Invest. 96:2966-2974.
25. Raine, C. S., B. Cannella, S. L. Hauser, and C. P. Genain. 1999. Demyelination in
primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for
antigen-specific antibody mediation. Ann.Neurol. 46:144-160.
26. Linington, C., B. Engelhardt, G. Kapocs, and H. Lassman. 1992. Induction of
persistently demyelinated lesions in the rat following the repeated adoptive transfer of
encephalitogenic T cells and demyelinating antibody. J.Neuroimmunol. 40:219-224.
27. Sun, J. B., T. Olsson, W. Z. Wang, B. G. Xiao, V. Kostulas, S. Fredrikson, H. P. Ekre,
and H. Link. 1991. Autoreactive T and B cells responding to myelin proteolipid
protein in multiple sclerosis and controls. Eur.J.Immunol. 21:1461-1468.
28. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P.
Schneider, T. Bornand, A. Fontana, D. Lienard, J. Cerottini, and J. Tschopp. 1996.
Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor
immune escape. Science. 274:1363-1366.
29. Andreola, G., L. Rivoltini, C. Castelli, V. Huber, P. Perego, P. Deho, P. Squarcina, P.
Accornero, F. Lozupone, L. Lugini, A. Stringaro, A. Molinari, G. Arancia, M. Gentile,
G. Parmiani, and S. Fais. 2002. Induction of Lymphocyte Apoptosis by Tumor Cell
Secretion of FasL-bearing Microvesicles. The Journal of Experimental Medicine
195:1303-1316.
30. Chappell, D. B., T. Z. Zaks, S. A. Rosenberg, and N. P. Restifo. 1999. Human
melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer.Res. 59:59-62.
31. Ferrone, S., J. F. Finerty, E. M. Jaffee, and G. J. Nabel. 2000. How much longer will
tumour cells fool the immune system? Immunol.Today. 21:70-72.
32. Finke, J., S. Ferrone, A. Frey, A. Mufson, and A. Ochoa. 1999. Where have all the T
cells gone? Mechanisms of immune evasion by tumors. Immunol.Today. 20:158-160.
33. Wang, E., G. Q. Phan, and F. M. Marincola. 2001. T-cell-directed cancer vaccines: the
melanoma model. Expert.Opin.Biol.Ther. 1:277-290.
34. Schiller, J. T. and D. R. Lowy. 2001. Papillomavirus-like particle based vaccines:
cervical cancer and beyond. Expert.Opin.Biol.Ther. 1:571-581.
35. Sun, Y., A. Paschen, and D. Schadendorf. 1999. Cell-based vaccination against
melanoma--background, preliminary results, and perspective. J.Mol.Med. 77:593-608.
36. Zauner, W., K. Lingnau, F. Mattner, A. von Gabain, and M. Buschle. 2001. Defined
synthetic vaccines. Biol.Chem. 382:581-595.
37. Hallek, M. and C. M. Wendtner. 1996. Recombinant adeno-associated virus (rAAV)
vectors for somatic gene therapy: recent advances and potential clinical applications.
Cytokines.Mol.Ther. 2:69-79.
38. Dietrich, G., A. Bubert, I. Gentschev, Z. Sokolovic, A. Simm, A. Catic, S. H.
Kaufmann, J. Hess, A. A. Szalay, and W. Goebel. 1998. Delivery of antigen-encoding
plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria
monocytogenes. Nat.Biotechnol. 16:181-185.
39. Holliger, P. and H. Hoogenboom. 1998. Antibodies come back from the brink.
Nat.Biotechnol. 16:1015-1016.
40. Hainsworth, J. D. 2000. Rituximab as first-line systemic therapy for patients with low-
grade lymphoma. Semin.Oncol. 27:25-29.
41. Hainsworth, J. D. 2000. Monoclonal antibody therapy in lymphoid malignancies.
Oncologist. 5:376-384.
42. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc
receptors modulate in vivo cytoxicity against tumor targets. Nat.Med. 6:443-446.
43. Rammensee, H. G., M. H. Julius, D. Nemazee, J. Langhorne, R. Lamers, and G.
Kohler. 1987. Targeting cytotoxic T cells to antigen-specific B lymphocytes.
Eur.J.Immunol. 17:433-436.
44. Ong, G. L. and M. J. Mattes. 1989. Mouse strains with typical mammalian levels of
complement activity. J.Immunol.Methods. %20;125:147-158.
45. Loibner, H., R. Plot, A. Rot, G. Werner, M. Wrann, H. Samonigg, M. Schmid, H.
Stoger, M. Truschnig, D. Herlyn, and . 1990. Immunoreactivity of patient with
colorectal cancer metastasis after immunisation with anti-idiotypes. Lancet.
%20;335:171.
46. Samonigg, H., M. Wilders-Truschnig, H. Loibner, R. Plot, A. Rot, I. Kuss, G. Werner,
H. Stoger, M. Wrann, D. Herlyn, and . 1992. Immune response to tumor antigens in a
patient with colorectal cancer after immunization with anti-idiotype antibody.
Clin.Immunol.Immunopathol. 65:271-277.
47. Samonigg, H., M. Wilders-Truschnig, I. Kuss, R. Plot, H. Stoger, M. Schmid, T.
Bauernhofer, A. Tiran, T. Pieber, L. Havelec, and H. Loibner. 1999. A double-blind
randomized-phase II trial comparing immunization with antiidiotype goat antibody
vaccine SCV 106 versus unspecific goat antibodies in patients with metastatic
colorectal cancer. J.Immunother. 22:481-488.
48. Baselga, J., L. Norton, J. Albanell, Y. M. Kim, and J. Mendelsohn. 1998.
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor
activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast
cancer xenografts. Cancer.Res. 58:2825-2831.
49. Loffler, A., P. Kufer, R. Lutterbuse, F. Zettl, P. T. Daniel, J. M. Schwenkenbecher, G.
Riethmuller, B. Dorken, and R. C. Bargou. 2000. A recombinant bispecific single-
chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity
by unstimulated T lymphocytes. Blood. 95:2098-2103.
50. Canfield, S. M. and S. L. Morrison. 1991. The binding affinity of human IgG for its
high affinity Fc receptor is determined by multiple amino acids in the CH2 domain
and is modulated by the hinge region. J.Exp.Med. 173:1483-1491.
51. Raum, T., R. Gruber, G. Riethmuller, and P. Kufer. 2001. Anti-self antibodies selected
from a human IgD heavy chain repertoire: a novel approach to generate therapeutic
human antibodies against tumor-associated differentiation antigens.
Cancer.Immunol.Immunother. 50:141-150.
52. Schluesener, H. J., R. A. Sobel, C. Linington, and H. L. Weiner. 1987. A monoclonal
antibody against a myelin oligodendrocyte glycoprotein induces relapses and
demyelination in central nervous system autoimmune disease. J.Immunol. 139:4016-
4021.
53. Goodell, E. M., S. Bilgin, and R. A. Carchman. 1978. Biochemical characteristics of
phagocytosis in the P388 D1 cell. Exp.Cell.Res. 114:57-62.
54. Zarcone, D., A. B. Tilden, G. Cloud, H. M. Friedman, A. Landay, and C. E. Grossi.
1986. Flow cytometry evaluation of cell-mediated cytotoxicity. J.Immunol.Methods.
%20;94:247-255.
55. Jacobs, D. B. and C. Pipho. 1983. Use of propidium iodide staining and flow
cytometry to measure anti-mediated cytotoxicity: resolution of complement-sensitive
and resistant target cells. J.Immunol.Methods. 62:101-108.
56. Windhagen, A., C. Scholz, P. Hollsberg, H. Fukaura, A. Sette, and D. A. Hafler. 1995.
Modulation of cytokine patterns of human autoreactive T cell clones by a single amino
acid substitution of their peptide ligand. Immunity. 2:373-380.
57. De Magistris, M. T., J. Alexander, M. Coggeshall, A. Altman, F. C. Gaeta, H. M.
Grey, and A. Sette. 1992. Antigen analog-major histocompatibility complexes act as
antagonists of the T cell receptor. Cell. 68:625-634.
58. Ashkenazi, A. and S. M. Chamow. 1997. Immunoadhesins as research tools and
therapeutic agents. Curr.Opin.Immunol. 9:195-200.
59. Chamow, S. M. and A. Ashkenazi. 1996. Immunoadhesins: principles and
applications. Trends.Biotechnol. 14:52-60.
60. Moore, A., C. J. Donahue, K. D. Bauer, and J. P. Mather. 1998. Simultaneous
measurement of cell cycle and apoptotic cell death. Methods.Cell.Biol. 57:265-
78.:265-278.
61. Idink-Mecking, C. A., D. J. Richel, I. Vermes, M. R. Schaafsma, C. Reutelingsperger,
and C. Haanen. 1998. Ex vivo evidence of lymphocyte apoptosis in hairy cell
leukemia, induced by 2-chlorodeoxyadenosine treatment. Ann.Hematol. 76:25-29.
62. Vermes, I., C. Haanen, H. Steffens-Nakken, and C. Reutelingsperger. 1995. A novel
assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on
early apoptotic cells using fluorescein labelled Annexin V. J.Immunol.Methods.
184:39-51.
63. Vermes, I., C. Haanen, D. J. Richel, M. R. Schaafsma, E. Kalsbeek-Batenburg, and C.
P. Reutelingsperger. 1997. Apoptosis and secondary necrosis of lymphocytes in
culture. Acta.Haematol. 98:8-13.
64. Ober, R. J., C. G. Radu, V. Ghetie, and E. S. Ward. 2001. Differences in promiscuity
for antibody-FcRn interactions across species: implications for therapeutic antibodies.
Int.Immunol. 13:1551-1559.
65. Fassler, R., K. Martin, E. Forsberg, T. Litzenburger, and A. Iglesias. 1995. Knockout
mice: how to make them and why. The immunological approach.
Int.Arch.Allergy.Immunol. 106:323-334.
66. Litzenburger, T., H. Bluthmann, P. Morales, D. Pham-Dinh, A. Dautigny, H. Wekerle,
and A. Iglesias. 2000. Development of myelin oligodendrocyte glycoprotein
autoreactive transgenic B lymphocytes: receptor editing in vivo after encounter of a
self-antigen distinct from myelin oligodendrocyte glycoprotein. J.Immunol. 165:5360-
5366.
67. Maldonado-Lopez, R., T. De Smedt, B. Pajak, C. Heirman, K. Thielemans, O. Leo, J.
Urbain, C. R. Maliszewski, and M. Moser. 1999. Role of CD8alpha+ and CD8alpha-
dendritic cells in the induction of primary immune responses in vivo. J.Leukoc.Biol.
66:242-246.
68. Maldonado-Lopez, R., T. De Smedt, P. Michel, J. Godfroid, B. Pajak, C. Heirman, K.
Thielemans, O. Leo, J. Urbain, and M. Moser. 1999. CD8alpha+ and CD8alpha-
subclasses of dendritic cells direct the development of distinct T helper cells in vivo.
J.Exp.Med. 189:587-592.
69. Iglesias, A., J. Bauer, T. Litzenburger, A. Schubart, and C. Linington. 2001. T- and B-
cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune
encephalomyelitis and multiple sclerosis. Glia. 36:220-234.
70. Amor, S., N. Groome, C. Linington, M. M. Morris, K. Dornmair, M. V. Gardinier, J.
M. Matthieu, and D. Baker. 1994. Identification of epitopes of myelin oligodendrocyte
glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and
Biozzi AB/H mice. J.Immunol. 153:4349-4356.
71. Kalbus, M., B. T. Fleckenstein, M. Offenhausser, M. Bluggel, A. Melms, H. E. Meyer,
H. G. Rammensee, R. Martin, G. Jung, and N. Sommer. 2001. Ligand motif of the
autoimmune disease-associated mouse MHC class II molecule H2-A(s).
Eur.J.Immunol. 31:551-562.
72. Karpovsky, B., J. A. Titus, D. A. Stephany, and D. M. Segal. 1984. Production of
target-specific effector cells using hetero-cross-linked aggregates containing anti-
target cell and anti-Fc gamma receptor antibodies. J.Exp.Med. 160:1686-1701.
73. Staerz, U. D. and M. J. Bevan. 1985. Cytotoxic T lymphocyte-mediated lysis via the
Fc receptor of target cells. Eur.J.Immunol. 15:1172-1177.
74. Staerz, U. D., O. Kanagawa, and M. J. Bevan. 1985. Hybrid antibodies can target sites
for attack by T cells. Nature. 314:628-631.
75. Valerius, T., B. Stockmeyer, A. B. van Spriel, R. F. Graziano, van den Herik-Oudijk
IE, R. Repp, Y. M. Deo, J. Lund, J. R. Kalden, M. Gramatzki, and J. G. van De
Winkel. 1997. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody
therapy. Blood. 90:4485-4492.
76. Segal, D. M., G. J. Weiner, and L. M. Weiner. 1999. Bispecific antibodies in cancer
therapy. Curr.Opin.Immunol. 11:558-562.
77. Withoff, S., W. Helfrich, L. F. de Leij, and G. Molema. 2001. Bi-specific antibody
therapy for the treatment of cancer. Curr.Opin.Mol.Ther. 3:53-62.
78. Todorovska, A., R. C. Roovers, O. Dolezal, A. A. Kortt, H. R. Hoogenboom, and P. J.
Hudson. 2001. Design and application of diabodies, triabodies and tetrabodies for
cancer targeting. J.Immunol.Methods. 248:47-66.
79. Weiner, L. M. 2000. Bispecific antibodies in cancer therapy. Cancer.J.Sci.Am. 6 Suppl
3:S265-71.:S265-S271.
80. de Leij, L., G. Molema, W. Helfrich, and B. J. Kroesen. 1998. Bispecific antibodies
for treatment of cancer in experimental animal models and man. Adv.Drug.Deliv.Rev.
31:105-129.
81. Wang, H., Y. Liu, L. Wei, and Y. Guo. 2000. Bi-specific antibodies in cancer therapy.
Adv.Exp.Med.Biol. 465:369-80.:369-380.
82. Koelemij, R., P. J. Kuppen, C. J. van de Velde, G. J. Fleuren, M. Hagenaars, and A.
M. Eggermont. 1999. Bispecific antibodies in cancer therapy, from the laboratory to
the clinic. J.Immunother. 22:514-524.
83. de Gast, G. C., J. G. van De Winkel, and B. E. Bast. 1997. Clinical perspectives of
bispecific antibodies in cancer. Cancer.Immunol.Immunother. 45:121-123.
84. van Spriel, A. B., H. H. van Ojik, and J. G. van De Winkel. 2000. Immunotherapeutic
perspective for bispecific antibodies. Immunol.Today. 21:391-397.
85. De Jonge, J., C. Heirman, M. de Veerman, S. Van Meirvenne, M. Moser, O. Leo, and
K. Thielemans. 1998. In vivo retargeting of T cell effector function by recombinant
bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the
murine BCL1 lymphoma model. J.Immunol. 161:1454-1461.
86. Cochlovius, B., S. M. Kipriyanov, M. J. Stassar, J. Schuhmacher, A. Benner, G.
Moldenhauer, and M. Little. 2000. Cure of Burkitt's lymphoma in severe combined
immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and
CD28 costimulation. Cancer.Res. 60:4336-4341.
87. Cochlovius, B., S. M. Kipriyanov, M. J. Stassar, O. Christ, J. Schuhmacher, G.
Strauss, G. Moldenhauer, and M. Little. 2000. Treatment of human B cell lymphoma
xenografts with a CD3 x CD19 diabody and T cells. J.Immunol. 165:888-895.
88. Kipriyanov, S. M., G. Moldenhauer, J. Schuhmacher, B. Cochlovius, C. W. der Lieth,
E. R. Matys, and M. Little. 1999. Bispecific tandem diabody for tumor therapy with
improved antigen binding and pharmacokinetics. J.Mol.Biol. 293:41-56.
89. Keck, P. C. and J. S. Huston. 1996. Symmetry of Fv architecture is conducive to
grafting a second antibody binding site in the Fv region. Biophys.J. 71:2002-2011.
90. Mack, M., G. Riethmuller, and P. Kufer. 1995. A small bispecific antibody construct
expressed as a functional single-chain molecule with high tumor cell cytotoxicity.
Proc.Natl.Acad.Sci.U.S.A. 92:7021-7025.
91. Goldstein, J., R. F. Graziano, K. Sundarapandiyan, C. Somasundaram, and Y. M. Deo.
1997. Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) x
epidermal growth factor bispecific fusion protein. J.Immunol. 158:872-879.
92. Graziano, R. F., J. Goldstein, K. Sundarapandiyan, C. Somasundaram, T. Keler, and
Y. M. Deo. 1997. Targeting tumor cell destruction with CD64-directed bispecific
fusion proteins. Cancer.Immunol.Immunother. 45:124-127.
93. Kreitman, R. J. 1999. Immunotoxins in cancer therapy. Curr.Opin.Immunol. 11:570-
578.
94. Vallera, D. A., S. Y. Seo, A. Panoskaltsis-Mortari, J. D. Griffin, and B. R. Blazar.
1999. Targeting myeloid leukemia with a DT(390)-mIL-3 fusion immunotoxin: ex
vivo and in vivo studies in mice. Protein.Eng. 12:779-785.
95. Litzenburger, T., R. Fassler, J. Bauer, H. Lassmann, C. Linington, H. Wekerle, and A.
Iglesias. 1998. B lymphocytes producing demyelinating autoantibodies: development
and function in gene-targeted transgenic mice. J.Exp.Med. 188:169-180.
96. Wines, B. D., M. S. Powell, P. W. Parren, N. Barnes, and P. M. Hogarth. 2000. The
IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc
gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized
by neonatal FcR and protein A.  J.Immunol. 164:5313-5318.
97. Williams, T. E., S. Nagarajan, P. Selvaraj, and C. Zhu. 2000. Concurrent and
independent binding of Fcgamma receptors IIa and IIIb to surface-bound IgG.
Biophys.J. 79:1867-1875.
98. Williams, T. E., P. Selvaraj, and C. Zhu. 2000. Concurrent binding to multiple ligands:
kinetic rates of CD16b for membrane-bound IgG1 and IgG2. Biophys.J. 79:1858-
1866.
99. Shields, R. L., A. K. Namenuk, K. Hong, Y. G. Meng, J. Rae, J. Briggs, D. Xie, J. Lai,
A. Stadlen, B. Li, J. A. Fox, and L. G. Presta. 2001. High resolution mapping of the
binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and
FcRn and design of IgG1 variants with improved binding to the Fc gamma R.
J.Biol.Chem. 276:6591-6604.
100. Ghetie, V. and E. S. Ward. 2000. Multiple roles for the major histocompatibility
complex class I- related receptor FcRn.  Annu.Rev.Immunol. 18:739-66.:739-766.
101. Medesan, C., P. Cianga, M. Mummert, D. Stanescu, V. Ghetie, and E. S. Ward. 1998.
Comparative studies of rat IgG to further delineate the Fc:FcRn interaction site.
Eur.J.Immunol. 28:2092-2100.
102. Gergely, J. and G. Sarmay. 1990. The two binding-site models of human IgG binding
Fc gamma receptors. FASEB.J. 4:3275-3283.
103. Jefferis, R., J. Lund, and J. D. Pound. 1998. IgG-Fc-mediated effector functions:
molecular definition of interaction sites for effector ligands and the role of
glycosylation. Immunol.Rev. 163:59-76.:59-76.
104. Link, H., O. Olsson, J. Sun, W. Z. Wang, G. Andersson, H. P. Ekre, T. Brenner, O.
Abramsky, and T. Olsson. 1991. Acetylcholine receptor-reactive T and B cells in
myasthenia gravis and controls. J.Clin.Invest. 87:2191-2195.
105. Stanley, J. R. 1997. Update: structure and function of pemphigus vulgaris antigen.
J.Dermatol. 24:741-743.
106. Hjelmstrom, P., A. E. Juedes, J. Fjell, and N. H. Ruddle. 1998. B-cell-deficient mice
develop experimental allergic encephalomyelitis with demyelination after myelin
oligodendrocyte glycoprotein sensitization. J.Immunol. 161:4480-4483.
107. Dittel, B. N., T. H. Urbania, and C. A. Janeway, Jr. 2000. Relapsing and remitting
experimental autoimmune encephalomyelitis in B cell deficient mice. J.Autoimmun.
14:311-318.
108. Genain, C. P., K. Abel, N. Belmar, F. Villinger, D. P. Rosenberg, C. Linington, C. S.
Raine, and S. L. Hauser. 1996. Late complications of immune deviation therapy in a
nonhuman primate. Science. %20;274:2054-2057.
109. Amagai, M. 1999. Autoimmunity against desmosomal cadherins in pemphigus.
J.Dermatol.Sci. 20:92-102.
110. Zisman, E., Y. Katz-Levy, M. Dayan, S. L. Kirshner, M. Paas-Rozner, A. Karni, O.
Abramsky, C. Brautbar, M. Fridkin, M. Sela, and E. Mozes. 1996. Peptide analogs to
pathogenic epitopes of the human acetylcholine receptor alpha ásubunit as potential
modulators of myasthenia gravis. PNAS 93:4492-4497.
111. Merchant, A. M., Z. Zhu, J. Q. Yuan, A. Goddard, C. W. Adams, L. G. Presta, and P.
Carter. 1998. An efficient route to human bispecific IgG. Nat.Biotechnol. 16:677-681.
112. Fuchs, S. 1979. Immunology of the nicotinic acetylcholine receptor.
Curr.Top.Microbiol.Immunol. 85:1-29.:1-29.
113. Drachman, D. B. 1996. Immunotherapy in neuromuscular disorders: current and future
strategies. Muscle.Nerve. 19:1239-1251.
114. Drachman, D. B., S. Okumura, R. N. Adams, and K. R. McIntosh. 1996. Oral
tolerance in myasthenia gravis. Ann.N.Y.Acad.Sci. 778:258-72.:258-272.
115. Manfredi, A. A., M. P. Protti, M. W. Dalton, J. F. Howard, Jr., and B. M. Conti-
Tronconi. 1993. T helper cell recognition of muscle acetylcholine receptor in
myasthenia gravis. Epitopes on the gamma and delta subunits. J.Clin.Invest. 92:1055-
1067.
116. Moiola, L., M. P. Protti, A. A. Manfredi, M. H. Yuen, J. F. Howard, Jr., and B. M.
Conti-Tronconi. 1993. T-helper epitopes on human nicotinic acetylcholine receptor in
myasthenia gravis. Ann.N.Y.Acad.Sci. 681:198-218.:198-218.
117. Protti, M. P., A. A. Manfredi, R. M. Horton, M. Bellone, and B. M. Conti-Tronconi.
1993. Myasthenia gravis: recognition of a human autoantigen at the molecular level.
Immunol.Today. 14:363-368.
118. Hawke, S., H. Matsuo, M. Nicolle, G. Malcherek, A. Melms, and N. Willcox. 1996.
Autoimmune T cells in myasthenia gravis: heterogeneity and potential for specific
immunotargeting. Immunol.Today. 17:307-311.
119. Tzartos, S. J., M. E. Seybold, and J. M. Lindstrom. 1982. Specificities of antibodies to
acetylcholine receptors in sera from myasthenia gravis patients measured by
monoclonal antibodies. Proc.Natl.Acad.Sci.U.S.A. 79:188-192.
120. Barchan, D., M. C. Souroujon, S. H. Im, C. Antozzi, and S. Fuchs. 1999. Antigen-
specific modulation of experimental myasthenia gravis: nasal tolerization with
recombinant fragments of the human acetylcholine receptor alpha-subunit.
Proc.Natl.Acad.Sci.U.S.A. 96:8086-8091.
121. Im, S. H., D. Barchan, S. Fuchs, and M. C. Souroujon. 1999. Suppression of ongoing
experimental myasthenia by oral treatment with an acetylcholine receptor recombinant
fragment. J.Clin.Invest. 104:1723-1730.
122. Barchan, D., O. Asher, S. J. Tzartos, S. Fuchs, and M. C. Souroujon. 1998.
Modulation of the anti-acetylcholine receptor response and experimental autoimmune
myasthenia gravis by recombinant fragments of the acetylcholine receptor.
Eur.J.Immunol. 28:616-624.
123. Souroujon, M. C., D. Barchan, and S. Fuchs. 1998. Modulation of experimental
autoimmune myasthenia gravis by recombinant fragments of the human acetylcholine
receptor. Ann.N.Y.Acad.Sci. 841:572-5.:572-575.

11. Curriculum vitae
S. Marcel Zocher, geboren am 21. Januar 1974 in Korbach, Deutschland
Universität Tübingen und Micromet AG, Martinsried Nov. 1999 bis Juni 2002
Promotionsarbeit
angefertigt am Max-Planck-Institut für Neurobiologie und in der Micromet AG
Betreuer: Prof. Patrick A. Baeuerle
Betreuer an der Universität Tübingen: Prof. Hans-Georg Rammensee
Universität Freiburg und MPI für Immunbiologie, Deutschland         1994 bis Okt. 1999
Diplom in Biologie (Hauptfach: Molekulare Immunologie)
Foothill College, Los Altos Hills, California, USA                               Jan. 1992 - Dez. 1993
Associate in Science Degree (A.S.) mit Auszeichnung (Honors). Hauptfach: Physik
Mountain View High School, California, USA                                      Feb. 1991 - Jan. 1992
Andreae - Gymnasium, Herrenberg, Germany                                       1984 - 1991
Im Selbstverlag herausgegeben von:
Zocher, Marcel
Ludwigstr. 2
82110 Germering

